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Regulation of Serum Albumin Production by Insulin
Abstract
Diabetes is accompanied by dysregulation of glucose, lipid, and protein metabolism. In recent years,
much effort has been spent on understanding how insulin regulates glucose and lipid metabolism, while
the effect of insulin on protein metabolism has received less attention. In diabetes, hepatic production of
serum albumin decreases, and it has long been established that insulin positively controls albumin gene
expression. Yet, the detailed pathway via which insulin exerts this effect has not been described. In this
study, we used a genetic approach in mice to identify the mechanism by which insulin regulates albumin
production, both transcriptionally and post-transcriptionally. Albumin expression was significantly
decreased in livers with insulin signaling disrupted by ablation of insulin receptor or Akt. Concomitant
deletion of Forkhead Box O1 (Foxo1) in these livers rescued the decreased albumin secretion.
Furthermore, expressing a constitutively active Foxo1 in the liver is sufficient to suppress albumin
expression. Mammalian Target of Rapamacin Complex 1 (mTORC1) activity had a minor contribution to
serum albumin production. Hepatic autophagy also played a minor role and contributed to albumin
production post-transcriptionally in the absence of insulin signaling. In addition, we show that constitutive
activation of Foxo1 is correlated with decreased occupancy of CCAAT/Enhancer Binding Protein α (C/
EBPα) at the albumin promoter. These results demonstrate that serum albumin production is regulated
mainly on the transcription level, and insulin stimulates albumin expression by inhibiting Foxo1, which
acts as a gene repressor of albumin by directly or indirectly interfering with C/EBPα binding to the
albumin promoter.
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ABSTRACT

REGULATION OF SERUM ALBUMIN PRODUCTION BY INSULIN
Qing Chen
Morris J. Birnbaum, M.D., Ph.D.

Diabetes is accompanied by dysregulation of glucose, lipid, and protein
metabolism. In recent years, much effort has been spent on understanding how
insulin regulates glucose and lipid metabolism, while the effect of insulin on
protein metabolism has received less attention. In diabetes, hepatic production
of serum albumin decreases, and it has long been established that insulin
positively controls albumin gene expression. Yet, the detailed pathway via which
insulin exerts this effect has not been described. In this study, we used a genetic
approach in mice to identify the mechanism by which insulin regulates albumin
production, both transcriptionally and post-transcriptionally. Albumin expression
was significantly decreased in livers with insulin signaling disrupted by ablation of
insulin receptor or Akt. Concomitant deletion of Forkhead Box O1 (Foxo1) in
these livers rescued the decreased albumin secretion. Furthermore, expressing
a constitutively active Foxo1 in the liver is sufficient to suppress albumin
expression. Mammalian Target of Rapamacin Complex 1 (mTORC1) activity had
a minor contribution to serum albumin production. Hepatic autophagy also
played a minor role and contributed to albumin production post-transcriptionally
iv

in the absence of insulin signaling. In addition, we show that constitutive
activation of Foxo1 is correlated with decreased occupancy of CCAAT/Enhancer
Binding Protein α (C/EBPα) at the albumin promoter. These results demonstrate
that serum albumin production is regulated mainly on the transcription level, and
insulin stimulates albumin expression by inhibiting Foxo1, which acts as a gene
repressor of albumin by directly or indirectly interfering with C/EBPα binding to
the albumin promoter.
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Chapter 1

General Introduction

1

Serum albumin: function, production, and regulation
Physiological function of serum albumin
Albumin is the most abundant plasma protein, accounting for ~60% of all
proteins in circulation. Synthesized solely in the liver at a high rate (12-25 grams
per day in a healthy adult), albumin has important physiological functions and is
also implicated in various disease states (Fanali et al., 2012). Serum albumin is
the main determinant of colloid osmotic pressure and modulates the fluid
distribution between intravascular and extravascular compartments. With its
binding capacity for a myriad of ligands, albumin serves as a key carrier for both
endogenous biomolecules, including cholesterol, fatty acids, and metal ions, and
exogenous compounds such as drugs. In addition, albumin exhibits anti-oxidant
effects and also functions as a free-radical scavenger to maintain a balanced
oxidative environment in plasma (Evans, 2002; Fanali et al., 2012; Nicholson,
2000; Peters, 1995).
In the clinical setting, serum albumin is frequently used as a cheap and
reliable biomarker for various diseases. For instance, due to its elevated uptake
into solid tumors and sites with high levels of inflammation, low albumin is proven
to be a useful indicator for cancer and rheumatoid arthritis. In addition to its
application in diagnosis, albumin is often administered to treat and manage
various diseases including burns, hemorrhage, and liver disease (Evans, 2002;
Fanali et al., 2012; Nicholson, 2000; Peters, 1995). Furthermore, albumin has
the potential to function as an effective drug carrier (Kratz, 2008).
2

Regulation of albumin production
The colloid osmotic pressure of the interstitial fluid surrounding the
hepatocytes is the most important regulator for albumin production. Indeed,
intravenous infusion in rats with macromolecules, such as albumin, globulins,
and dextran, cause a decrease in transcriptional activity of albumin (Pietrangelo
et al., 1992). This observation demonstrates an effective feedback mechanism
to maintain the homeostatic concentration of albumin in circulation.
The proper hormonal environment is also essential for optimal albumin
synthesis. Insulin is required for adequate albumin synthesis and controls
albumin production at the transcription level (discussed in more details below).
Glucocorticoids are also an essential regulator for albumin transcription, as
adrenalectomized rats exhibit decreased albumin expression (Nawa et al., 1986).
Consistent with this result, albumin transcription in primary rat hepatocytes can
be stimulated by dexamethasone treatment (Hutson et al., 1987; Kimball et al.,
1995; Nawa et al., 1986). Growth hormone, when added to primary hepatocyte
culture, also has a stimulatory effect on albumin expression (Johnson et al.,
1991). Albumin synthesis and secretion are inhibited by glucagon (Dich and
Gluud, 1976; Masumoto et al., 1988; Tavill et al., 1973; Uchida et al., 1991),
although the inhibitory effect of glucagon on albumin production is likely post
transcriptional: Nawa et al. found that while glucagon enhances albumin gene
transcription induced by dexamethasone, glucagon alone has no effect on
albumin expression (Nawa et al., 1986).
3

Finally, nutritional state plays a significant role in albumin production.
Prolonged starvation decreases albumin production in liver (Kelman et al., 1972).
This is possibly due to limited availability of amino acids under this condition, as it
was observed that culturing primary rat hepatocytes in amino acids-deficient
media leads to decreased albumin mRNA and secretion (Hutson et al., 1987;
Kelman et al., 1972; Nawa et al., 1986). Among essential amino acids, leucine,
isoleucine, and tryptophan have stimulatory effects on albumin production
(Hutson et al., 1987). Amino acids also regulate albumin synthesis in vivo, as
rats fed a low-protein diet exhibit reduced albumin expression and protein
secretion (Nawa et al., 1986).

Regulation of albumin production by insulin
Over 30 years ago, Peavy and colleagues found that albumin production
is significantly reduced in alloxan-induced Type 1 diabetic rats. Parallel with this
change, abundance of albumin mRNA in the liver is also reduced. Administration
of insulin in these animals can restore both albumin mRNA and secretion (Peavy
et al., 1978). A similar observation was made in spontaneously diabetic rats,
where insulin deficiency causes a decreases in albumin mRNA and synthesis,
and this defect is eliminated with insulin treatment (Jefferson et al., 1983). These
studies highlight the stimulatory effect of insulin on hepatic albumin production by
regulating the quantity of albumin mRNA.

4

More biochemical studies have since demonstrated that insulin stimulates
albumin production on the level of transcription. Since the apparent half-life of
albumin mRNA is unaltered in diabetic rats, degradation of mRNA is unlikely to
be the underlying mechanism. Furthermore, the size of albumin-synthesizing
polysomes and the ribosomal half-transit time are comparable between diabetic
and control rats, suggesting that the translation efficiency of the albumin
message is not changed (Peavy et al., 1985). Using primary rat hepatocyte
culture (Flaim et al., 1985), Lloyd et al. definitely showed that insulin stimulates
albumin transcription, which directly correlates with albumin mRNA and secretion
levels (Lloyd et al., 1987).
Consistent with observations made in animal models, Type 1 diabetic
patients undergoing an insulin withdrawal exhibit significantly reduced albumin
secretion, indicating that insulin positively regulates albumin production in human
subjects as well (De Feo et al., 1991). Defects in serum albumin production
might be specific to the type of diabetes, as the albumin synthetic rate is normal
in Type 2 diabetic patients, and insulin can stimulate albumin production to the
same extent in Type 2 diabetic patients as in control subjects (Tessari et al.,
2006b). This observation suggests that the regulation of albumin production by
insulin is intact in Type 2 diabetes, which could be explained by the model of
selective insulin (See Chapter 2, “Discussion”, and Chapter 4, “Serum albumin
production is intact in Type 2 diabetes”).

Significance
5

As described previously, serum albumin performs a myriad of important
physiological functions, including controlling oncotic pressure and modulating
drug metabolism. Under conditions of malnutrition, caused by diabetes,
starvation, or protein deficiency, albumin expression and production are
decreased. Hypoalbuminemia, often manifested as swelling, muscular
symptoms, loss of appetite, ascites, and pleural effusions, would lead to
dysregulation of albumin-mediated processes. Since treatment of
hypoalbuminemia requires treating the underlying cause, it is therefore crucial to
understand the regulatory mechanism of albumin production in order to devise
the most effective treatment paradigm. This study will shed light on the
molecular basis of how serum albumin production is regulated by insulin.

Insulin signaling and its physiological function
Overview of the physiological role of insulin
Insulin is a pivotal hormone that regulates metabolism and growth
(Bedinger and Adams, 2015; Biddinger and Kahn, 2006; Saltiel and Kahn, 2001).
Upon nutrient influx, insulin is secreted from pancreatic β-cells in response to the
rising blood glucose level. In peripheral tissues such as fat and muscle, insulin
stimulates nutrient uptake and storage, while inhibiting nutrient breakdown and
release. Specifically, insulin promotes glucose uptake into cells by mediating the
translocation of the glucose transporter, GLUT4, to the cell membrane. In
adipocytes, insulin activates the lipogenic pathway to convert glucose to
6

triglycerides for long-term energy storage. Simultaneously, insulin inhibits
lipolysis via inactivation of hormone-sensitive lipase (HSL), thereby preventing
the release of free fatty acids and glycerol into circulation. In muscle, insulin
stimulates the net production of glycogen from dietary glucose (Bedinger and
Adams, 2015; Biddinger and Kahn, 2006; Saltiel and Kahn, 2001). Liver is
another major site of insulin action. Hepatic glucose production is turned off by
insulin as a result of its inhibition of gluconeogenesis and glycogenolysis.
Moreover, insulin signaling switches the liver from fatty acids oxidation to a net
production and secretion of lipids (Bedinger and Adams, 2015; Biddinger and
Kahn, 2006). Overall, insulin mediates the whole-body postprandial response
and maintains glucose and lipid homeostasis.

The insulin signaling pathway
The insulin signaling cascade is initiated by insulin binding to its receptor.
The insulin receptor (IR) is a heterodimeric complex, and each dimer contains an
α subunit and a β subunit. The β subunits of IR contain intrinsic tyrosine kinase
activity that is repressed by the α subunits in the absence of insulin. Upon insulin
binding to the α subunits, the β subunits become derepressed and
transphosphorylate each other, resulting in full activation of IR. Downstream of
IR, tyrosine residues on insulin receptor substrate (IRS) are phosphorylated and
serve as docking sites for proteins containing Src homology 2 (SH2) domains. In
the case of insulin signaling, the protein that docks on phosphorylated IRS is
phosphatidylinositol 3-kinase (PI3K), which phosphorylates phosphoinositides at
7

the 3-position to produce PIP3. PIP3 binds various signaling molecules via their
pleckstrin homology (PH) domains, thereby activating them or changing their
cellular localization. Downstream of PI3K activation and PIP3 generation, two
events occur that lead to the activation of Akt or protein kinase B (PKB): First,
phosphoinositide-dependent kinase 1 (PDK1), the upstream activator of Akt,
becomes activated as a result of PIP3 accumulation; Second, Akt is recruited to
the plasma membrane in the vicinity of PDK1 to be phosphorylated at Thr308
and activated (Biddinger and Kahn, 2006; Saltiel and Kahn, 2001). The Rictorcontaining mammalian target of rapamycin complex (mTORC2) also directly
phosphorylates Akt at Ser473 for its full activation (Sarbassov et al., 2005).
Although phosphorylation at Ser473 is not required for phosphorylation at
Thr308, mTORC2-mediated phosphorylation seems to determine Akt specificity
(Jacinto et al., 2006; Shiota et al., 2006).
Several pathways downstream of Akt mediate insulin’s effects on
metabolism. Akt phosphorylates and inactivates glycogen synthase kinase 3
(GSK3), relieving the repression on glycogen synthase and thus promoting
glycogen synthesis (Cross et al., 1995). On another branch, Akt phosphorylates
and inactivates the Tuberous Sclerosis 1/2 complex (TSC1/2), thereby releasing
the inhibition of mammalian target of rapamycin complex 1 (mTORC1) (Inoki et
al., 2002; Sengupta et al., 2010). Akt also activates mTORC1 by
phosphorylating proline-rich Akt substrate of 40kDa (PRAS40), causing it to
dissociate from mTORC1 and relieving its inhibitory constraint on mTORC1
activity (Wiza et al., 2012). In addition to Akt signaling, mTORC1 activity is
8

stimulated by amino acids (Sancak et al., 2010). AMP-activated protein kinase
(AMPK), when activated by depleted cellular energy levels, phosphorylates the
mTOR binding partner Raptor and leads to inactivation of mTORC1 (Gwinn et al.,
2008). Downstream of insulin signaling, activation of mTORC1 stimulates protein
synthesis as well as lipogenesis (Düvel et al., 2010; Laplante and Sabatini, 2010;
Li et al., 2010; Thoreen et al., 2012; Wang and Proud, 2006). Finally, Akt
phosphorylates the transcription factor forkhead box O1 (Foxo1), causing its
translocation out of the nucleus (Biggs et al., 1999; Nakae et al., 1999; Rena,
2002; Rena et al., 1999). Foxo1 binds directly to the insulin response elements
(IREs) in the promoters of key gluconeogenic enzymes to stimulate the
expression of these genes under fasting conditions. Under postprandial
conditions, when insulin is present, Foxo1 is located largely in the cytoplasm and
thus becomes inactive as a transcription factor (Hall et al., 2000; Schmoll et al.,
2000). Foxo1 can act as either a transcription activator or a repressor, although
the detailed mechanism by which it represses gene expression is not yet fully
understood (see below).

Impairment of insulin signaling and the development of Type 2 diabetes
Diabetes is a growing pandemic, affecting about 29 million people in the
United States and creating a huge economic toll on the health care system. The
disease is caused by failed production of (Type 1 diabetes) or dampened
response to insulin (Type 2 diabetes). In Type 2 diabetes, insulin action is
reduced, causing dysregulation of glucose and lipid metabolism. As a result,
9

Type 2 diabetic patients exhibit hyperglycemia and hyperlipidemia. To
compensate for insulin resistance, insulin secretion from the pancreas is
increased, resulting in hyperinsulinemia. Although both in vivo and in vitro
studies have contributed to the understanding of the pathogenesis of insulin
resistance and Type 2 diabetes, much of this complex metabolic disease remains
to be understood (Bedinger and Adams, 2015; Biddinger and Kahn, 2006; Saltiel
and Kahn, 2001).

Foxo1 as a transcriptional repressor
Overview
Genetic studies in C. elegans suggest that DAF-16, the Foxo ortholog,
functions as a transcriptional activator downstream of the insulin/IGF-1 signaling
(IIS) pathway by binding directly to the insulin response elements (IREs) in the
promoter. However, DNA binding is not required for DAF-16 to repress gene
expression for a different set of genes. Therefore, genes that are downregulated
by DAF-16 (Class II genes) are more likely indirect targets (Murphy et al., 2003;
Schuster et al., 2010; Tepper et al., 2013). Recently, Tepper et al. described an
elusive transcriptional activator, PQM-1, that is mutually antagonistic with DAF16 with regard to subcellular localization in response to IIS, providing a
mechanism for the regulation of Class II genes (Tepper et al., 2013). To date, it
is unclear whether a similar mechanism exists in mammals. Recent studies have
suggested that Foxo1 potentially functions as a repressor indirectly by either
10

inducing the expression of a transcriptional repressor, or modulating the activity
of another transcription factor.

Foxo1 induces expression of transcription repressors
Small heterodimer partner (Shp) interacts with and represses a range of
nuclear receptors and transcription factors including liver X receptor alpha
(LXRα) and hepatic nuclear factor 4α (Hnf-4α) to regulate cholesterol catabolism
(Boulias et al., 2005; Huang et al., 2007; Park et al., 2011). It has been
demonstrated that Foxo1 directly binds to the promoter of Shp and activates its
expression (Shin et al., 2012; Wei et al., 2011). In addition, Shp also plays a role
in liver metabolism consistent with it being a direct downstream target of Foxo1.
Shp is induced in ob/ob and diet-induced obese livers. Shp-transgenic mice
exhibit elevated hepatic triglyceride and bile acid, whereas Shp-null mice are
protected from diet-induced obesity and hepatic steatosis. Furthermore, deletion
of Shp improves insulin sensitivity and completely reverses hepatic steatosis in
ob/ob mice (Boulias et al., 2005; Huang et al., 2007; Park et al., 2011). Another
transcriptional repressor, inhibitor of DNA binding protein 3 (Id3), a basic helixloop-helix (bHLH) protein that forms heterodimer and inhibits other bHLH
proteins, is also identified as a Foxo1 target that is implicated in liver
regeneration and development. (Shin et al., 2012). Interestingly, both Shp and
Id3 might be involved in the regulation of albumin expression. Park et al. found
that Shp physically interacts with C/EBPα, a transcriptional activator known to
regulate albumin gene expression (see below) and represses its activity (Park et
11

al., 2007). In chick liver development, Id3 and albumin show reciprocal
expressions both spatially and temporally (Nakayama et al., 2006).

Foxo1 modulates activity of other transcription factors
Ramaswamy et al. first demonstrated that Foxo1 can regulate gene
expression independent of DNA-binding (Ramaswamy et al., 2002). Using a
mutant Foxo1 that lacks DNA binding, the authors identified three classes of
genes regulated by Foxo1 through transcriptional profiling. Class I genes are
induced by Foxo1, and such induction requires DNA binding of Foxo1.
Interestingly, a Foxo1 mutant lacking DNA-binding is able to induce and repress
Class II and Class III genes, respectively. Moreover, chromatin
immunoprecipitation using an antibody against Foxo1 shows that mutant Foxo1
is recruited to the promoter of Class II and Class III genes. These results
suggest a mechanism where Foxo1 regulates gene expression by interacting
with other transcription factors at the promoter. Indeed, it has been since
discovered that Foxo1 directly interacts with a wide range of transcription factors
to modulate their activity (Van der Vos and Coffer, 2008). For example, Foxo1
antagonizes the transcription activator activity of peroxisome proliferatoractivated receptor γ (PPARγ), a critical regulator of adipocyte differentiation, by
directly interacting with PPARγ and disrupting its DNA binding to the target genes
(Dowell, 2003; Fan et al., 2009). Similarly, Deng et al. recently described a
mechanism where Foxo1 directly interacts with Srebp-1c and interferes with its
12

binding to the Srebp1c promoter, thereby down regulating lipogenic genes (Deng
et al., 2012).

Transcription factors known to regulate albumin gene expression
Overview
The promoter region of the albumin gene contains six distinct elements
(Site A-F), recognized by several transcription factors (Lichtsteiner et al., 1987;
Maire et al., 1989). Site B and Site D have the highest activating potential,
whereas the rest of the sites have much less contribution to the promoter activity.
Moreover, Site B and Site D interact with liver-enriched transcription factors
known to regulate albumin gene expression, including hepatocyte nuclear factor
1α (Hnf-1α), CCAAT/enhancer binding protein α (C/EBPα), C/EBPβ, and D site
binding protein (Dbp) (Lichtsteiner et al., 1987; Maire et al., 1989).

Hepatic nuclear factor 1α (Hnf-1α)
Predominantly expressed in liver and kidney, Hnf-1α is a transcription
activator known to interact with many liver-specific genes, including albumin
(Tronche et al., 1989), β-fibrinogen (Courtois et al., 1987), and α1-antitrypsin
(Courtois et al., 1987; Monaci et al., 1988). Systemic inactivation of Hnf-1α leads
to stunted growth and increased mortality. Hnf-1α is also involved in cholesterol
and amino acid metabolism, as Hnf1a-deficient mice exhibits severe
hypercholesterolemia and hyperphenylalanemia. Importantly, genetic ablation of
13

Hnf1a leads to decreased hepatic expression of albumin as well as lower serum
albumin level (Lee et al., 1998; Pontoglio et al., 1996). These observations
highlight an important regulatory role of Hnf-1α on albumin gene expression.

D site binding protein (Dbp)
Dbp, a member of the B-ZIP family, binds to the D site of the albumin
promoter via its basic domain (Maire et al., 1989; Mueller et al., 1990).
Interestingly, accumulation of Dbp mRNA and protein follow a “free-running”
circadian pattern that is independent of feeding and drinking behaviors, where
Dbp mRNA and protein levels are the highest in the evening and are the lowest
in the morning (Wuarin and Schibler, 1990). Since Dbp knockout mice are still
rhythmic, Dbp is most likely the output of circadian pathway rather than a
regulator (Lopez-Molina, 1997). As a result of the circadian pattern of Dbp,
albumin expression is the most efficient in the evening, as demonstrated by runon experiments. Nevertheless, albumin expression does not fluctuate, probably
due to the long half-life of its mRNA (Wuarin and Schibler, 1990).

CCAAT/enhancer binding protein α and β (C/EBP α and β)
C/EBP α and β are key regulators to control cell differentiation and
proliferation (Nerlov, 2008). Highly expressed in liver, adipose, and lung, these
transcription factors play a significant role in liver metabolism, adipogenesis,
female fertility, and hermatopoiesis. Structurally, C/EBPs contain a conserved
14

DNA-binding and dimerization domain, and a C-terminal basic region-leucine
zipper (bZIP) domain that mediates protein-protein interaction with other
transcription factors (Nerlov, 2007), which provides an additional layer of
regulation for C/EBPs function (see below). In addition, both C/EBPα and
C/EBPβ exist in multiple isoforms as a result of alternative translation initiation.
Work by Calkhoven et al. demonstrates that the relative ratio of C/EBP isoforms
controls cell differentiation and cell fate (Calkhoven et al.).
C/EBPα plays a significant role in regulating whole-body metabolism.
Congenital whole-body Cebpa knockout mice die shortly after birth due to defects
in glycogen storage in the liver and subsequently hypoglycemia, suggesting that
C/EBPα is required for mediating energy homeostasis in neonates (Wang et al.,
1995). In liver, in addition to being a potent trans-activator for the albumin gene
(Friedman et al., 1989), C/EBPα is also important in other liver functions,
including bilirubin clearance and ammonia detoxification (Inoue et al., 2004; Y H
Lee, 1997). Furthermore, C/EBPα is also a key mediator of glucose and lipid
metabolism in liver, regulating the expression of gluconeogenic and lipogenic
enzymes to mediate glycogen synthesis, hepatic glucose production, and lipid
synthesis in the liver (Inoue et al., 2004; Matsusue et al., 2004; Qiao, 2006; Y H
Lee, 1997).
Often acting together with C/EBPα as a heterodimer, C/EBPβ plays similar
roles in mediating glucose and lipid metabolism in liver (Croniger et al., 2000;
1997; Liu et al., 1999; Millward et al., 2007; Rahman et al., 2007; SchroederGloeckler et al., 2007). Importantly, C/EBPβ exists in two isoforms: a 35kDa liver
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activating protein (LAP) and a 20kDa liver inhibitory protein (LIP). LAP and LIP
are translated from the same mRNA transcript as a result of leaky ribosome
scanning. LIP, lacking the transactivation domain, exhibits higher binding affinity
for DNA and functions as a dominant inhibitor of C/EBP family members
(Descombes and Schibler, 1991). Therefore, the transcriptional activity of a
C/EBPβ target genes is dependent on the LAP/LIP ratio (Nerlov, 2008; Van der
Vos and Coffer, 2008). It has been previously shown that LAP/LIP ratio is altered
during terminal liver differentiation, ER stress, and inflammation (Hu et al., 2004;
Li et al., 2008; Luedde et al., 2004). However, the regulatory mechanism
controlling the relative synthesis and degradation of LAP and LIP remains
unclear.

Autophagy and its regulatory role in metabolism
Overview
Autophagy, which translates to “eating oneself”, is an evolutionarily
conserved quality control process that degrades and recycles damaged cellular
components and organelles, and the broken-down constituents are in turn used
for either biosynthesis or energy generation (Kim and Lee, 2014; Rabinowitz and
White, 2010; Yamada and Singh, 2012). There are three kinds of autophagy:
Macroautophagy (referred to as “autophagy” hereafter), characterized by the
formation of autophagosomes, is responsible for the turnover of organelles and
proteins. Microautophagy, on the other hand, involves the formation of single16

membraned vesicles, which then pinch off within the lysosomal lumen for the
degradation of the enclosed content (Sahu et al., 2011). Finally, chaperonemediated autophagy is a degradation process selective for soluble cytosolic
proteins with the KFERQ signature (Arias and Cuervo, 2011). Under basal
conditions, constitutive autophagy plays an important housekeeping role to
maintain cellular functions and energy balance. In the event of metabolic stress,
such as starvation, the process of self-cannibalization is a key source of nutrients
to meet the energy demand. Recently, numerous studies have demonstrated
that autophagy is an essential mediator of energy homeostasis, and
dysregulation of autophagy has direct implications in various diseases including
metabolic disorders, neurodegenerative diseases, and cancer (Kim and Lee,
2014; Rabinowitz and White, 2010; Yamada and Singh, 2012).

Autophagy mediates whole-body metabolism
Dispensable during embryonic development, autophagy is induced at birth
in various tissues, including heart, lung, and diaphragm, and remains high for 12
hours in neonates before returning to basal levels (Kuma et al., 2004).
Autophagy-deficient mice exhibit significantly reduced level of amino acids and
die within 1 day of birth (Komatsu, 2005; Kuma et al., 2004; Sou et al., 2008).
Somewhat surprisingly, blood glucose and lipid levels of autophagy-deficient
mice are comparable with wildtype littermates, suggesting that in neonates, the
major role of autophagy is to provide amino acids from breaking down in-house
proteins (Kuma et al., 2004). These studies have demonstrated that neonates
17

utilize autophagy to maintain energy balance at birth, when nutrient supply is
suddenly disrupted.
Autophagy has also been implicated in aging. Well-established regimens
that extend life span, including caloric restriction, TOR inhibition, and genetic
manipulation of the insulin signaling cascade, all stimulate the autophagy
pathway. Furthermore, in many of these cases, the longevity-promoting effects
are dependent on autophagy (Madeo et al., 2010; Rubinsztein et al., 2011).
Recently, Pyo et al. demonstrated that ubiquitous overexpression of Atg5 in mice
extends lifespan significantly (17.2%), and the animals exhibit a list of anti-aging
phenotypes such as reduced adiposity, enhanced insulin sensitivity, and
improved motor function (Pyo et al., 2013). These observations highlight the
cytoprotective role of autophagy and further emphasize the important role of
autophagy in maintaining metabolic homeostasis. The metabolic role of
autophagy in adipose tissue and liver is summarized below.
Autophagy in adipose tissue
Autophagy in adipose tissue has a critical role in adipocyte differentiation
and adipogenesis. Mice with fat-specific disruption of autophagy are lean and
exhibit significantly reduced fat mass compared to wild type controls.
Morphological studies reveal that autophagy-deficient adipocytes are smaller and
have multilocular lipid droplets, larger cytosol, and increased number of
mitochondria. Consistent with increased mitochondrial content, β-oxidation of
fatty acids is increased in these animals. Furthermore, white adipose tissue with
disrupted autophagy exhibit features of brown fat, including increased levels of
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UCP1. Due to altered adipose physiology, fat-specific Atg7 knockout mice have
enhanced insulin sensitivity and are protected from high-fat-diet-induced obesity
(Singh et al., 2009a; Zhang et al., 2009).
Autophagy in adipose tissue is also associated with obesity, insulin
resistance, and the development of Type 2 diabetes. In both mice and human,
autophagy in adipose tissue is elevated in obese subjects compared to lean
controls. In addition, when compared to insulin-sensitive subjects, insulinresistant individuals exhibit higher levels of autophagic activity in the adipose
tissue (Jansen et al., 2012; Kovsan et al., 2010). Consistent with this
observation, patients with Type 2 diabetes show strongly upregulated autophagy
in their adipocytes (Anita Öst, 2010). One proposed mechanism by which
autophagy contributes to the development of insulin resistance in adipocytes is
mediating the degradation of insulin receptor, downstream of the elevated level
of ER stress (Zhou et al., 2009).

Autophagy in liver
In liver, autophagy mediates energy metabolism in response to hormonal
signals and nutrient availability (Yin et al., 2008). Mice with autophagy disrupted
specifically in the liver exhibit severe hepatomegaly, increased hepatic protein
content, and accumulation of deformed peroxisomes, mitochondria, and ER,
suggesting that liver autophagy plays a significant role in the regulation of liver
mass and the removal of dysfunctional organelles (Komatsu, 2005; Yin et al.,
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2008). Hepatic autophagy also contributes to the metabolic processes in liver.
Singh and colleagues discovered that autophagy negatively regulates the
intracellular lipid stores in liver, a process they referred to as “macrolipophagy”.
Consistent with this finding, they also observed that disruption of hepatic
autophagy cause increased hepatic triglyceride content and total lipid droplets in
hepatocytes (Singh et al., 2009a). In addition to lipid metabolism, autophagy
also contributes to glucose production by supplying amino acids as
gluconeogenic precursors during starvation (Ezaki et al., 2011).
In addition to having a metabolic role, autophagy also plays a significant
regulatory role in mediating liver metabolism. Opposite of what is observed in
the adipose tissue, hepatic autophagy is suppressed during obesity (Liu et al.,
2009; Singh et al., 2009a; Yang et al., 2010). This indicates that the metabolic
function of autophagy is tissue-specific. Recently, Yang et al. showed that
suppressing autophagy impairs insulin signaling both in vitro and in vivo, as
measured by phosphorylation of IR and Akt upon insulin stimulation. On the
contrary, inducing hepatic autophagy in leptin-deficient ob/ob mice increases
insulin signaling, reduces steatosis, and improves systemic glucose homeostasis
(Yang et al., 2010). Thus, there might be value in targeting hepatic autophagy as
a therapeutic intervention against obesity and insulin resistance.
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Chapter 2

Insulin stimulates albumin gene expression by inhibiting Foxo1
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Introduction
Synthesized solely in the liver, serum albumin is the most abundant
circulating protein, accounting for ~60% of total serum proteins. In addition to
being the major determinant of oncotic pressure, albumin also functions as the
carrier for many endogenous and exogenous compounds, including free fatty
acids, ions, and drugs. Clinically, albumin is a crucial biomarker used to assess
liver function (Fanali et al., 2012). Multiple factors, including nutritional states,
oncotic pressure, and hormonal factors, regulate albumin production (Kimball et
al., 1995; Pietrangelo et al., 1992; Sakuma et al., 1987). In Type 1 diabetes, the
concentration of albumin in blood is decreased, and administration of insulin is
required to prevent hypoalbuminemia (De Feo et al., 1991; Jefferson et al.,
1983). Early biochemical studies have shown that insulin stimulates albumin
production in the liver by activating gene transcription (De Feo et al., 1991; Flaim
et al., 1985; Hutson et al., 1987; Jefferson et al., 1983; Kimball et al., 1995; Lloyd
et al., 1987; Peavy et al., 1978; 1985). Yet, the detailed pathway by which insulin
exerts this effect has not been described.
In liver, insulin promotes protein production and lipid synthesis, while
turning off gluconeogenesis and glycogenolysis (Brown and Goldstein, 2008;
Cross et al., 1995; Leavens and Birnbaum, 2011; Saltiel and Kahn, 2001). The
insulin signaling pathway has been well characterized: insulin binds to the insulin
receptor (IR), which leads to phosphorylation of the insulin receptor substrate
(IRS). This then initiates a cascade of signaling events that results in the
phosphorylation and activation of Akt protein kinases (Saltiel and Kahn, 2001).
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Several pathways downstream of Akt mediate insulin’s effects on metabolism.
Akt phosphorylates and inactivates the Tuberous Sclerosis 1/2 (TSC1/TSC2)
complex, thereby releasing the inhibition of mammalian target of rapamycin
complex 1 (mTORC1) (Inoki et al., 2002; Sengupta et al., 2010). Activation of
mTORC1 stimulates protein synthesis as well as lipogenesis (Düvel et al., 2010;
Laplante and Sabatini, 2010; Li et al., 2010; Thoreen et al., 2012; Wang and
Proud, 2006). Akt also phosphorylates the transcription factor forkhead box O1
(Foxo1), causing its translocation out of the nucleus (Biggs et al., 1999; Nakae et
al., 1999; Rena, 2002; Rena et al., 1999). Foxo1 binds directly to the insulin
response elements (IREs) in the promoters of key gluconeogenic enzymes to
stimulate the expression of these genes under fasting conditions. Under
postprandial conditions when insulin is present, Foxo1 is located largely in the
cytoplasm and thus becomes inactive as a transcription factor (Hall et al., 2000;
Schmoll et al., 2000).
Autophagy, literally translated as “self-eating”, is a mechanism where
cellular constituents are engulfed in compartments called autophagosomes and
delivered to the lysosome for degradation. Since its first description by de Duve
and Wattiaux in 1966, autophagy has been extensively characterized.
Autophagy has been implicated in human pathology, including
neurodegenerative disease, cancer, and aging (Rabinowitz and White, 2010;
Rubinsztein et al., 2011; Yamada and Singh, 2012). Moreover, autophagy is
emerging as a critical component in the regulation of metabolism, as recent
studies demonstrate its role in lipid and glucose metabolism (He et al., 2012; Liu
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et al., 2009; Singh et al., 2009b; Yang et al., 2010). Furthermore, autophagy has
been linked with pancreatic beta cell function and insulin action (Ebato et al.,
2008; Jung et al., 2008). These observations suggest that autophagy, in addition
to its cytoprotective role, is also an important metabolic modulator.
In the present study, we used a genetic approach to address the
longstanding question of the mechanism by which insulin stimulates albumin
transcription. We found that insulin acts directly on the liver through the
IR/PI3K/Akt pathway to inhibit Foxo1, which functions as a repressor of albumin
expression. Interestingly, elevated hepatic autophagy also contributes to serum
albumin production, possibly by supplying amino acid, generating energy, and/or
augmenting protein secretion.

Results
Albumin gene expression is reduced in Type 1, but not Type 2, diabetic livers
First, we assessed the effect of diabetes on albumin expression in mice.
Steptozotocin (STZ), a compound that induces β-cell death, is frequently used to
induce Type 1 diabetes in animal models. Mice injected with STZ developed
severe hyperglycemia (Figure 2.1A) and lost a significant amount of body weight
(Figure 2.1B). In addition, albumin gene expression in liver was significantly
decreased compared to control animals (Figure 2.1C). Consistent with early
studies in rats, this result suggests that insulin positively regulates hepatic
albumin production on the level of transcription. We did not observe a difference
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in serum albumin level between STZ-treated and control animals (not shown),
possibly because the half-life of albumin protein is longer than the duration of the
experiment (21 days and 11 days, respectively).
Next, we used the leptin-deficient (ob/ob) mouse model to address
whether albumin production is also reduced in Type 2 diabetes. Interestingly,
despite of having severe insulin resistance, ob/ob animals exhibited slightly
elevated level of total serum protein and albumin gene expression compared to
control (Figure 2.2 A and B). These results suggest that albumin transcription
and production are slightly increased in Type 2 diabetic livers.

Insulin signals directly on the liver to stimulate albumin gene expression
To assess whether the regulation of insulin on albumin production is a
cell-autonomous effect, we deleted insulin receptor (Ir) specifically in the liver
(IRKO, Figure 2.3A). Serum albumin level was significantly reduced in IRKO
animals compared to controls (GFP, Figure 2.3B). Consistent with the reduced
circulating albumin protein level, albumin gene expression in IRKO livers was
significantly decreased compared to controls (Figure 2.3C). These results
suggest that insulin controls albumin production by signaling directly on the liver.
It is also worthwhile to note that a short-term (overnight) fast did not affect
the steady-state serum albumin level or albumin expression level in either IRKO
or control livers, as there was no significant difference between the overnightfasted state and the fasted-refed state (Figure 2.3B and C). Rather than
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measuring the newly synthesized species, here, total albumin protein and mRNA
levels were measured. Since the half-life of these species exceeds the duration
of overnight fasting, the stimulatory effect of insulin on albumin expression and
protein level could not be observed.

Akt is required for proper albumin gene expression and production
Akt is an essential downstream signaling molecule that mediates various
metabolic effects of insulin. We then investigated whether Akt is required to
regulate albumin production downstream of IR. To this end, we deleted the only
isoforms of Akt expressed in liver, Akt1 and Akt2, specifically in the liver
(AktDKO, Figure 2.4A). AktDKO mice exhibited a 50% reduction in serum
albumin compared to control (GFP, Figure 2.4B). This severe hypoalbuminemia
was correlated with a dramatic decrease in albumin gene expression (Figure
2.4C).
To address whether this albumin production defect is cell-autonomous, we
isolated primary hepatocytes from GFP and AktDKO mice and measured
albumin secretion in vitro. AktDKO hepatocytes secreted significantly less
albumin compared to control (Figure 2.4D). Consistent with the reduced albumin
secretion, albumin gene expression in AktDKO hepatocytes was significantly
decreased (Figure 2.4E). Taken together, these results suggest that insulin
signals through the Akt pathway to control albumin transcription and secretion.
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Inhibition of Foxo1 is required for proper albumin expression and production
Foxo1, the transcription factor downstream of Akt, becomes constitutively
active when insulin signaling is disrupted. We asked whether inhibition of Foxo1
as a result of insulin signaling is required for maintaining albumin transcription.
Interestingly, additional deletion of Foxo1 in IRKO livers (FoxoDKO, Figure 2.5A)
fully restored the reduced circulating albumin level observed in IRKO mice
(Figure 2.5B). In addition, albumin expression in FoxoDKO livers was completely
restored to control levels (Figure 2.5C).
Similarly, additional deletion of Foxo1 in AktDKO livers (FoxoTKO, Figure
2.6A) almost completely restored serum albumin level (Figure 2.6B), and
completely restored the reduced albumin expression observed in AktDKO livers
(Figure 2.6C). This effect was cell-autonomous: primary hepatocytes isolated
from FoxoTKO livers exhibited comparable albumin secretion (Figure 2.6D) and
albumin gene expression (Figure 2.6E) as control. These results suggest that
insulin controls albumin transcription and secretion via, at least in part, the
inhibition of Foxo1.
We then investigated whether inhibiting Foxo1 is sufficient to correct the
reduced albumin expression in Type 1 diabetic livers. To this end, we used STZ
to induce diabetes in either control (GFP) or liver-specific Foxo1 knockout mice
(FoxoKO, Figure 2.7A). Both genotypes developed severe hyperglycemia post
STZ injection (Figure 2.7B). Importantly, STZ treatment in GFP mice caused a
50% reduction in albumin gene expression in liver, and this reduction was
completely absent in FoxoKO mice (Figure 2.7C). In addition, we found that
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transgenic mice expressing a constitutively active Foxo1 (CA-Foxo1) had
significantly reduced hepatic albumin expression compared to wildtype controls
(WT, Figure 2.8). These results suggest that constitutive activation of hepatic
Foxo1 is sufficient to repress albumin expression and contributes to decreased
albumin production in Typ1 diabetes.

Whether mTORC1 is required for proper albumin production is unclear
In addition to inhibiting Foxo1, Akt also phosphorylates and inhibits TSC1
to activate mTORC1, a major regulator for protein translation by activating S6
kinase. To investigate whether mTORC1 signaling also contributes to albumin
production, we first assessed the effect of restoring the reduced hepatic
mTORC1 activity in AktDKO mice. To this end, we concomitantly deleted Tsc1 to
generate liver-specific Tsc1/Akt1/Akt2 triple-knockout mice (TSC1TKO, Figure
2.9A). As indicated by the constitutively elevated levels of ribosomal protein S6
phosphorylation, mTORC1 in these livers was constitutively active in the absence
of hepatic Akt activity, regardless of the nutritional state (Figure 2.9A). While
TSC1TKO animals exhibited significantly reduced serum protein level when
compared to GFP controls, the defect was much milder than AktDKO animals
(~25% vs. 50% reduction, Figure 2.9B). Furthermore, concomitant deletion of
Tsc1 showed no improvement on the reduced albumin gene expression
observed in Akt-null livers (Figure 2.9C). These results suggest that mTORC1
signaling might contribute to hepatic albumin production post-transcriptionally.
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However, we obtained a contradictory result when we directly examined
the role of mTORC1 signaling on albumin production by deleting Raptor, an
essential component of mTORC1, specifically in the liver (RaptorKO, Figure
2.10A). The absence of mTORC1 activity was confirmed by the complete lack of
phosphorylated S6. In addition, as a result of decreased negative feedback
mediated by S6 kinase, Akt was hyper-phosphorylated in RaptorKO livers (Figure
2.10A). Both total serum protein concentration and albumin gene expression
level of RaptorKO mice were comparable to GFP controls (Figure 2.10B and C).
These results suggest that mTORC1 activity is not required to maintain hepatic
albumin production.

Elevated hepatic autophagy contributes to albumin production
Downstream of insulin/Akt signaling, mTORC1 inhibits autophagy, a
process important for cellular renewal and waste disposal. Recent studies have
shown that autophagy also plays a significant role in metabolic regulation and
insulin action. Since mice lacking Akt in the liver exhibited impaired mTORC1
activity, hepatic autophagy in these animals was elevated, as indicated by the
reduced level of p62, a protein degraded by autophagy (Figure 2.11). We then
asked whether elevated autophagy contributes to the reduced albumin
production in AktDKO animals.
First, we assessed the role of hepatic autophagy on albumin production in
wildtype animals. To this end, we deleted Atg5, an essential component of the
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autophagy pathway, specifically in the liver. Liver-specific Atg5 knockout
(Atg5KO) animals exhibited normal blood glucose level and body weight (Figure
2.12A and B). Consistent with previous observations in models with disrupted
hepatic autophagy, Atg5KO mice exhibited elevated liver weight compared to
GFP controls (Figure 2.12C and D). Interestingly, Atg5KO mice showed a small
decrease in total serum protein concentration in the overnight-fasted state but not
in the fasted-refed state (Figure 2.12E). Since autophagy is elevated during
fasting, this result suggests that active hepatic autophagy might contribute to
albumin production. Furthermore, albumin gene expression in Atg5KO mice was
normal (Figure 2.12F), suggesting that the role of autophagy on albumin
production is post-transcriptional.
Next, we assessed the effect of elevated hepatic autophagy in AktDKO
mice on albumin production. To this end, we concomitantly deleted Atg5 and
generated liver-specific Atg5/Akt1/Akt2 triple-knockout mice (Atg5TKO, Figure
2.13A). Interestingly, Atg5TKO mice developed severe edema, accumulating a
significant amount of fluid in the interstitial space (Figure 2.13B), indicating
severe dysregulation of oncotic pressure, most likely due to defects in albumin
production. Atg5TKO mice exhibited normal fasting glucose level and
significantly increased body weight (Figure 2.13C and D). The body weight
difference was mostly due to fluid accumulation (Figure 2.13E). Interestingly, the
liver weight of Atg5TKO mice was comparable to GFP controls (Figure 2.13F).
Since AktDKO livers were smaller, this result is consistent with previous
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observation that disrupting hepatic autophagy leads to an increase in liver
weight.
Disrupting hepatic autophagy in AktDKO livers exacerbated the reduced
serum protein level (Figure 2.14A), consistent with the severe edema phenotype
observed in Atg5TKO animals. Surprisingly, concomitant deletion of Atg5 not
only completely restored the reduced albumin gene expression observed in
AktDKO livers, albumin mRNA levels in these livers were even slightly increased
compared to GFP controls (Figure 2.14B).

Discussion
Early biochemical studies in rats have shown that insulin stimulates
albumin production in liver by activating gene transcription (De Feo et al., 1991;
Flaim et al., 1985; Hutson et al., 1987; Jefferson et al., 1983; Kimball et al., 1995;
Lloyd et al., 1987; Peavy et al., 1978; 1985). Similarly, mice with STZ-induced
Type 1 diabetes exhibited significantly reduced albumin gene expression
compared to control (Figure 2.1C). Yet, the detailed pathway via which insulin
regulates albumin gene expression has not been described. Here, we used a
genetic approach to systematically elucidate this pathway.
Deletion of the insulin receptor specifically in the liver led to a decrease in
both albumin gene expression and circulating albumin levels (Figure 2.3A and B),
suggesting that insulin signals directly on the liver to control albumin production.
This is consistent with previous observations described in Michael et al., where
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the liver-specific congenital Ir-knockout mice exhibit a 50% reduction in serum
albumin compared to wildtype control (Michael et al., 2000). The defect in our
IRKO mice was much milder (~25% reduction, Figure 2.3B), possibly because
our knockout model was acute and the animals were much younger (3 months
old vs. 6 months old).
Disruption of both isoforms of hepatic Akt specifically in the liver also
caused a significant reduction in both albumin gene expression and circulating
albumin levels (Figure 2.4A and B), suggesting that Akt is required downstream
of IR to mediate insulin’s effect on albumin production. Importantly, when
compared to the IRKO, AktDKO mice exhibited a larger defect, suggesting that
basal hepatic Akt activity in IRKO mice maintained some albumin gene
expression and protein production. Furthermore, Akt regulates albumin
production cell-autonomously, as hepatocytes isolated from AktDKO animals
exhibited decreased albumin gene expression and secreted less albumin protein
in vitro compared to control (Figure 2.4D and E).
To interrogate how albumin production is regulated downstream of Akt, we
first examined the role of Foxo1, a transcription factor phosphorylated and
inhibited by Akt. Foxo1 is an important target whose inhibition mediates many of
the actions of insulin. Liver-specific Foxo1 knockout mice phenocopy the effect
of insulin in having impaired glucose production (Matsumoto et al., 2007). In
addition, inhibition of hepatic Foxo1 activity protects against high-fat diet induced
hepatic insulin resistance (Kim et al., 2009; Xiong et al., 2013). On the other
hand, transgenic mice with liver-specific expression of constitutively active Foxo1
32

exhibit fasting hyperglycemia, reduced de novo lipogenesis and hepatic insulin
resistance (Zhang et al., 2006). These studies highlight that Foxo1 plays a
significant role in regulating glucose and lipid metabolism downstream of insulin
in liver. Here, we found that active Foxo1 also represses albumin expression. In
models where Foxo1 was constitutively active (IRKO, AktDKO, STZ-induced
diabetes), albumin gene expression was decreased and genetic ablation of
Foxo1 in these models completely restored the decreased albumin expression
(Figure 2.5, Figure 2.6, and Figure 2.7). Furthermore, we demonstrated that
constitutive activation of Foxo1 in liver was sufficient to decrease albumin gene
expression (Figure 2.8). Taken together, we conclude that insulin stimulates
albumin production by inhibiting Foxo1, which represses albumin expression.
Interestingly, even though concomitant deletion of Foxo1 completely
restored the reduced albumin gene expression in AktDKO livers, there remained
a small, yet statistically significant decrease in albumin protein level in serum,
suggesting that insulin may also regulate albumin production at a posttranscriptional site downstream of Akt. To this end, we investigated the role of
mTORC1, a complex known to stimulate protein translation downstream of
insulin, in serum albumin production.
Impaired mTORC1 activity in AktDKO liver also contributed to decreased
albumin production because when we restored mTORC1 activity by deleting
Tsc1 in addition to Akt1 and Akt2 specifically in the liver, serum albumin level
increased from 50% of control level to 75% of control (Figure 2.9B). mTORC1
contributed to albumin production on a post-transcription level, as albumin gene
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expression was not affected by restoring hepatic mTORC1 activity (Figure 2.9C).
Taken together, these results suggest that downstream of Akt, albumin gene
expression is controlled by Foxo1, whereas mTORC1 may contribute to posttranscriptional production of serum albumin, presumably on the level of protein
translation and/or secretion. Similarly, disrupting mTORC1 activity by deleting
Raptor specifically in the liver had no effect on albumin gene expression (Figure
2.10C). Surprisingly, serum protein level was not significantly reduced in the
absence of hepatic mTORC1 activity (Figure2.10B). At first glance, results in
TSC1TKO and RaptorKO livers seem to be inconsistent with regard to whether
mTORC1 contributes to serum albumin production. We speculate that normal
serum albumin level in RaptorKO animals might be the result of elevated hepatic
autophagy, which also contributes to albumin production (see below).
Nevertheless, mTORC1 exerts a relatively minor effect on serum albumin
production, suggesting that regulation of albumin transcription plays a more
dominant role than translational regulation in serum albumin production.
Autophagy is an important physiological process that maintains energy
balance, disposes misfolded proteins, and removes damaged cellular
compartments. Autophagy is activated by increased cellular stress and inhibited
by activation of mTORC1 (Rabinowitz and White, 2010; Yamada and Singh,
2012). As a result of dampened mTORC1 activity in AktDKO livers, autophagy
was elevated, as indicated by the decreased level of p62, a protein degraded by
autophagy (Figure 2.11). We asked whether increased autophagy contributed to
the reduced production of albumin observed in AktDKO animals.
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Our results indicate that in postprandial state, autophagic activity is low
and exerts little effect on albumin production. On the other hand, we observed a
small yet statistically significant decrease in serum protein level in overnight
fasted Atg5KO animals (Figure 2.12E), suggesting that opposite to what we
expected, hepatic autophagy, a catabolic process, positively contributes to serum
albumin production. Furthermore, this level of regulation occurred at a posttranscriptional site, as disruption of hepatic autophagy did not affect albumin
gene expression level (Figure 2.12F).
Deletion of Atg5 in addition to Akt1 and Akt2 specifically in the liver
(Atg5TKO) led to the development of severe edema. Atg5TKO mice
accumulated significant amount of fluid (equivalent to a third of body weight) in
the interstitial space (Figure 2.13B-E), suggesting that oncotic pressure in these
animals was severely dysregulated. Atg5TKO animals exhibited normal liver
weight compared to controls (Figure 2.13F). Since Akt-null livers were smaller
than controls, this implies that disruption of hepatic autophagy in this model also
induced hepatomegaly. Consistent with the edema phenotype, serum protein of
Atg5TKO animals was significantly reduced compared to controls (Figure2.14A).
Interestingly, this reduction was exacerbated compared to AktDKO animals
(~70% reduction vs. ~50% reduction, respectively), suggesting that activation of
autophagy in AktDKO livers maintained some albumin production. This is
consistent with our previous observation, where activation of hepatic autophagy
during fasting positively contributed to albumin production.
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How hepatic autophagy contributes to albumin production is currently
unclear. One possible mechanism is that autophagy generates substrates
intracellularly to supply protein synthesis, since amino acids released from
autophagic degradation can potentially be recycled for protein production (Narita
et al., 2011; Rabinowitz and White, 2010). In addition, it is possible that the
products of autophagic degradation are used for energy generation to support
hepatic protein production (He et al., 2012; Rabinowitz and White, 2010; Singh et
al., 2009b). It has been demonstrated recently that autophagy is also involved in
both conventional and unconventional secretory pathways. Notably, in
senescent cells, autophagosomes co-localize with mTORC1 to form the TORautophagy spatial coupling compartment (TASCC). This co-localization allows
for spatial coupling of autophagic degradation, which generates a high flux of
substrates, directly with mTORC1-mediated biosynthesis for efficient synthesis
and secretion of proteins in these cells (Narita et al., 2011). It is possible that
such compartment also exists in liver, and autophagy contributes to albumin
production by augmenting its secretion.
Somewhat surprisingly, we also observed disconnect between serum
albumin level and albumin gene expression in Atg5TKO animals. Specifically,
even though serum protein levels in these animals were dramatically decreased,
hepatic albumin mRNA was slightly increased compared to controls (Figure
2.14B). We speculate this is the result of the feedback mechanism in response
to the drastic decrease in oncotic pressure, the main regulator of albumin
synthesis (Fanali et al., 2012; Nicholson, 2000). It has been shown that
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intravenous infusion of macromolecules in rats can decrease the transcriptional
activity of albumin to compensate for the increase in oncotic pressure
(Pietrangelo et al., 1992). In Atg5TKO animals, oncotic pressure was
significantly reduced as a result of severely reduced albumin production, and it is
possible that albumin transcription was stimulated as a compensatory
mechanism. It is important to note that under this model, oncotic pressure
regulates albumin transcription by a pathway independent of Akt.
In contrast to what was observed in STZ-induced Type 1 diabetic animals,
serum albumin production and transcription are slightly elevated in leptindeficient animals, suggesting differential regulation of albumin by insulin in Type
1 versus Type 2 diabetes. Consistent with this result, studies in human patients
also showed that serum albumin production is not affected by Type 2 diabetes
(Tessari et al., 2006b). The increased albumin expression and protein level in
leptin-deficient animals are likely the compensatory induction as a result of
albuminuria in these animals (Hudkins et al., 2010; Tessari et al., 2006a).
Alternatively, our result suggests that insulin action on serum albumin production
is maintained during insulin resistance, and the increased albumin gene
expression could be the result of hyperinsulinemia in these animals. During
insulin resistance, insulin’s ability to stimulate glucose uptake and to inhibit
hepatic glucose production is impaired, yet insulin continues to stimulate de novo
lipogenesis, resulting hypertriglyceridemia. Currently, there are two prevailing
views to explain the paradoxical pathology of metabolic disease. Under the
model of “selective insulin resistance”, only specific metabolic pathways are
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resistant to insulin while the others remain intact: insulin fails to suppress hepatic
glucose production, while continuing to sustain hepatic lipogenesis (Brown and
Goldstein, 2008). It is possible that in Type 2 diabetes, the regulation of insulin
on albumin production also remains intact. An alternative model suggests that
rather than impaired insulin action, the metabolic defects are mainly caused by
altered substrate delivery and nutrient handling (Otero et al., 2014). Under this
model, our result would imply that transcription and secretion of serum albumin is
unaffected by altered nutrient flux to the liver during insulin resistance.
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Figure 2.1: Albumin expression is decreased in Type 1 diabetic livers.
A,B. (A) Blood glucose and (B) body weight of mice that received an intraperitoneal injection of either control buffer (Ctrl) or Steptozotocin (STZ) at 200mg
per kg body weight.
C. Hepatic albumin mRNA level measured 9 days post STZ injection.
All values are expressed as mean ± SEM. n = 3-5; *p<0.05 vs. Ctrl by two-tailed
Student’s t-test.
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Figure 2.2: Albumin expression and production are normal in Type 2
diabetic livers.
A. Total protein concentration in serum of wildtype (WT) and leptin-deficient
(ob/ob) mice.
B. Hepatic albumin mRNA levels of WT and ob/ob mice.
All values are expressed as mean ± SEM. n = 4-5; *p<0.05 vs. WT and **p<0.01
vs. WT by two-tailed Student’s t-test.
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Figure 2.3: Insulin signals directly in the liver to stimulate albumin
expression.
A. Western blots for insulin receptor (IR) and actin in liver homogenates of GFP
control (GFP) and liver-specific Ir knockout (IRKO) animals.
B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in
GFP and IRKO animals that had been either fasted overnight or fasted overnight
and refed for 4 hours.
All values are expressed as mean ± SEM. n = 3-6; **p<0.01 vs. GFP and
***p<0.001 vs. GFP by two-way ANOVA using Sidak post-test.
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Figure 2.4: Akt is required to mediate insulin’s effect on albumin
production.
A. Western blots for Akt1, Akt2, and actin in liver homogenates of GFP control
(GFP) and liver-specific Akt1/Akt2 double-knockout (AktDKO) animals.
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B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in
GFP and AktDKO animals that had been either fasted overnight or fasted
overnight and refed for 4 hours. n = 3-4; **p<0.01 vs. GFP by two-way ANOVA
using Sidak post-test.
D. A representative experiment of in vitro albumin secretion assay. Primary
hepatocytes isolate from GFP and AktDKO livers were cultured in serum-free
media for 2 hours. Secreted proteins were TCA precipitated and subjected to
Western blot for albumin. Experiment was repeated 3 times.
E. Albumin mRNA level in primary hepatocytes isolated from GFP and AktDKO
livers were assayed by RT-qPCR. n = 3-4; **p<0.01 vs. GFP by two-tailed
Student’s t-test.
All values are expressed as mean ± SEM.
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Figure 2.5: Inhibition of Foxo1 restores reduced albumin production in
liver-specific insulin receptor knockout mice.
A. Western blots for insulin receptor (IR), Foxo1, and actin in liver homogenates
of GFP control (GFP) and liver-specific Ir/Foxo1 double-knockout (FoxoDKO)
animals.
B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in
GFP, liver-specific Ir knockout (IRKO), and FoxoDKO animals that had been
either fasted overnight or fasted overnight and refed for 4 hours.
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All values are expressed as mean ± SEM. n = 4-5; ns, not significant, *p<0.05 vs.
GFP, and ***p<0.001 vs. WT by two-way ANOVA using Sidak post-test.
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Figure 2.6: Inhibition of Foxo1 restores reduced albumin production in
liver-specific Akt1/Akt2 double-knockout mice.
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A. Western blots for Akt1, Akt2, Foxo1, and actin in liver homogenates of GFP
control (GFP) and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO)
animals.
B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in
GFP, liver-specific Akt1/Akt2 double-knockout (AktDKO), and FoxoTKO animals
that had been either fasted overnight or fasted overnight and refed for 4 hours. n
= 3-5; ns, not significant, **p<0.01 vs. GFP, and ***p<0.001 vs. GFP by two-way
ANOVA using Sidak post-test.
D. A representative experiment of in vitro albumin secretion assay. Primary
hepatocytes isolated from GFP and FoxoTKO livers were cultured in serum-free
media for 2 hours. Secreted proteins were TCA precipitated and subjected to
Western blot for albumin. Experiment was repeated 3 times.
E. Albumin mRNA level in primary hepatocytes isolated from GFP and FoxoTKO
livers were measured by RT-qPCR. n = 3-4; ns, not significant by two-tailed
Student’s t-test.
All values are expressed as mean ± SEM.
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Figure 2.7: Inhibition of Foxo1 restores reduced albumin expression in
streptozotocin-induced Type 1 diabetic livers.
A. Western blots for Foxo1 and lamin in liver nuclear extracts of GFP control
(GFP) and liver-specific Foxo1 knockout (FoxoKO) animals.
B,C. Blood glucose (B) and hepatic albumin mRNA level (C) of GFP and FoxoKO
animals 9 days post an intra-peritoneal injection of either buffer (Ctrl) or
streptozotocin (STZ) at 200mg per kg body weight.
All values are expressed as mean ± SEM. n = 5-7; ns, not significant, **p<0.01
vs. Ctrl and ***p<0.001 vs. Ctrl by two-way ANOVA using Sidak post-test.
48

Alb mRNA

Fold Change

1.5

1.0

**
0.5

0.0

WT

CA-Foxo1

Figure 2.8: Activation of hepatic Foxo1 is sufficient to suppress albumin
expression.
Hepatic albumin mRNA level of wildtype (WT) and liver-specific transgenic mice
expressing a constitutively active Foxo1 (CA-Foxo1) were measured by RTqPCR.
All values are expressed as mean ± SEM. n = 3; **p<0.01 vs. WT by two-tailed
Student’s t-test.
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Figure 2.9: Activation of mTORC1 partially restores reduced albumin
production in liver-specific Akt1/Ak2 double-knockout mice with no effect
on albumin gene expression.
A. Western blots for tuberculosis sclerosis complex (TSC) 1, TSC2,
phosphorylated Akt (S473), Akt2, phosphorylated ribosomal protein S6
(S235/S236), and ribosomal protein S6 in liver homogenates of GFP control
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(GFP) and liver-specific Tsc1/Akt1/Akt2 triple-knockout (TSC1TKO) animals that
had been either fasted overnight or fasted overnight and refed for 4 hours.
B-D. Total protein concentration in serum (C) and albumin mRNA level (D) in
GFP and TSC1TKO animals that had been either fasted overnight or fasted
overnight and refed for 4 hrs.
All values are expressed as mean ± SEM. n = 4-5; ns, not significant and
***p<0.001 vs. GFP by two-way ANOVA using Sidak post-test.
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Figure 2.10: mTORC1 is not required for proper hepatic albumin
production.
A. Western blots for Raptor, phosphorylated Akt (S473), phosphorylated
ribosomal protein S6 (S235/S236), ribosomal protein S6, and tubulin in liver
homogenates of GFP control (GFP) and liver-specific Raptor knockout
(RaptorKO) animals that had been either fasted overnight or fasted overnight and
refed for 4 hours.
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B,C. Total protein concentration in serum (B) and hepatic albumin mRNA level
(C) of GFP and RaptorKO animals.
All values are expressed as mean ± SEM. n = 9; *p<0.05 vs. GFP and
***p<0.001 vs. GFP by two-tailed Student’s t-test.
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Figure 2.11: Disruption of Akt signaling in the liver leads to elevated
hepatic autophagy.
Immunohistochemical staining for p62, a protein degraded by autophagy, in GFP
control (GFP) and Akt-null (AktDKO) livers. Scale bars indicate 100µm.
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Figure 2.12: Disruption of hepatic autophagy in wildtype mice has no effect
on albumin production.
Blood glucose (A), body weight (B), liver weight (C), liver weight as a percent of
body weight (D), total protein concentration in serum (E), and hepatic albumin
mRNA level (F) of GFP control (GFP) or liver-specific Atg5 knockout (Atg5KO)
mice that had been either fasted over night or fasted overnight and refed for 4
hours.
All values are expressed as mean ± SEM. n = 4-5; ns, not significant, *p<0.05 vs.
GFP, **p<0.01 vs. GFP, and ***p<0.001 vs. GFP by two-way ANOVA using
Sidak post-test.
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Figure 2.13: Disruption of hepatic autophagy in liver-specific Akt1/Akt2
double-knockout mice causes severe edema.
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A. Western blots for Atg5, p62, Akt2, and ribosomal protein S6 in liver
homogenates of GFP control (GFP) and liver-specific Atg5/Akt1/Akt2 tripleknockout (Atg5TKO) animals.
B. Gross appearance of the peritoneal cavity of GFP and Atg5TKO mice.
C-F. Fasting blood glucose (C), body weight (D), skin and fluid weight (E,
obtained by subtracting the weight of dissected carcass from body weight), and
liver weight (F) of GFP and Atg5TKO mice.
All values are expressed as mean ± SEM. n = 6-9; ns, not significant and
***p<0.001 vs. GFP by two-tailed Student’s t-test.
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Figure 2.14: Disruption of hepatic autophagy in liver-specific Akt1/Akt2
double-knockout mice restores reduced albumin expression but not
reduced circulating albumin.
Total protein concentration in serum (A) and hepatic albumin mRNA level (B) in
GFP control (GFP) and liver-specific Atg5/Akt1/Akt2 triple-knockout (Atg5TKO)
mice.
All values are expressed as mean ± SEM. n = 6-9; *p <0.05 vs. GFP and
***p<0.001 vs. GFP by two-tailed Student’s t-test.
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Chapter 3

Mechanisms of albumin gene regulation downstream of Foxo1
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Introduction
Although the mechanism by which insulin regulates albumin transcription
has not been elucidated until the present study, the transcriptional regulation of
the albumin gene has been extensively characterized: Six distinct cis elements
in the promoter region have been identified, as well as a handful of liver-enriched
transcription factors that interact with the Alb promoter to activate albumin
transcription, including hepatic nuclear factor 1α (Hnf-1α), D site binding protein
(Dbp), and CCAAT/enhancer binding proteins (C/EBPs) (Lichtsteiner et al., 1987;
Maire et al., 1989). Of interest, C/EBPs are key regulators for cell differentiation
and proliferation (Nerlov, 2008). In liver, C/EBPs are essential for maintaining
normal liver functions such as albumin production and bilirubin detoxification and
clearance (Inoue et al., 2004; Y H Lee, 1997). In addition, C/EBPs control the
expression of key gluconeogenic and lipogenic enzymes, thus playing a
significant role in regulating glucose and lipid metabolism in liver as well.
In the previous chapter, we have demonstrated that insulin signals directly
on the liver to inhibit Foxo1, which functions as a transcriptional repressor of the
albumin gene. The specific mechanism of how Foxo1 functions as a repressor
remains largely unknown. Studies in C. elegans show that genes downregulated
by DAF-16, the Foxo ortholog, are not directly bound by DAF-16, suggesting that
Foxo represses gene expression by an indirect mechanism (Ramaswamy et al.,
2002; Tullet, 2014). A recent study described a transcription factor called PQM1, which exhibits subcellular localization that is mutually antagonistic with that of
DAF-16: When DAF-16 is active and nuclear, PQM-1 is excluded from the
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nucleus and subsequently its target genes are downregulated. This provides a
mechanism by which DAF-16 functions as a gene repressor (Tepper et al.,
2013). To date, it is unclear whether an orthologous mechanism exists in
mammals. Nevertheless, recent studies in mammalian systems have provided
evidence that Foxo1 could potentially repress gene expression by inducing the
expression of other transcriptional repressor(s), or modulating the activity of other
transcription factors.
In this chapter, we interrogated possible mechanisms by which Foxo1
represses albumin gene expression. We found that it is unlikely that Foxo1
induces the expression of small heterodimer partner (Shp) or inhibitor of DNA
binding protein 3 (Id3) to repress the albumin gene. Interestingly, the
transcriptional activity of C/EBPα was negatively correlated with Foxo1 activity.
Furthermore, using chromatin immunoprecipitation (ChIP), we found that
constitutive activation of Foxo1 was correlated with reduced C/EBPα binding to
the albumin promoter.

Results
Shp and Id3 are unlikely the transcriptional repressors for albumin gene
expression downstream of Foxo1
We first assessed the model in which Foxo1 functions as a repressor
indirectly by inducing the expression of a transcriptional repressor, which in turn
represses target genes. Shp and Id3 are transcription repressors that have been
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identified as putative targets of Foxo1 (Shin et al., 2012; Wei et al., 2011).
Moreover, previous studies have suggested connections between these factors
and albumin expression (Nakayama et al., 2006; Park et al., 2007). To test
whether Shp or Id3 represses albumin transcription downstream of Foxo1, we
first measured their gene expression in our genetic models. We found that for
both Shp and Id3, gene expression was significantly induced in Akt-null livers
where Foxo1 was constitutively active, and concomitant deletion of Foxo1
completely reversed the gene induction (Figure 3.1A and B). This observation is
consistent with previous studies that Foxo1 directly induces Shp and Id3
transcription. In addition, the reciprocal expression pattern between albumin and
Shp and Id3 is consistent with the model where Shp and/or Id3 repress albumin
expression. Nevertheless, the postprandial changes in Shp and Id3 gene
expression in control animals are inconsistent with the model where Foxo1
induces the expression of these repressors. Specifically, upon feeding when
Foxo1 becomes inhibited by insulin, Shp and Id3 expression should be
downregulated according to the model. Yet, our data shows that Shp expression
was unchanged and Id3 expression was induced (Figure 3.1A and B), suggesting
that Foxo1 might not be a physiologic regulator of Shp and Id3.
In addition, in Ir-null livers and streptozotocin (STZ)- induced diabetic
livers, where Foxo1 was also constitutively active, we did not observe an
induction of Shp or Id3 gene expression (Figure 3.1C-F). This inconsistency
suggests that the regulation of Shp and Id3 is more complex. Therefore, it is
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unlikely that Foxo1 represses albumin gene expression by inducing these
transcription repressors.

Gene expression of Cebpa was reduced in Akt-null livers
To investigate whether Foxo1 represses albumin expression by directly
affecting the activity of a transcription factor, we then shifted our attention to the
transcription factors known to regulate albumin expression. Distinct cisregulatory sites have been identified in the Alb promoter, as well as the
transcription factors bound at each site (Lichtsteiner et al., 1987; Maire et al.,
1989)(Figure 3.2A). Notably, all factors identified are transcription activators.
We decided to focus on examining C/EBPα, C/EBPβ, Dbp, and Hnf-1α because
these transcription factors are liver-enriched and are associated with binding
sites with the strongest activating potential (Maire et al., 1989).
We first measured the hepatic gene expression levels of these
transcription factors. Interestingly, we found that Cebpa showed a significant
decrease in gene expression when Ir was specifically deleted in the liver (IRKO)
in the fasted state and exhibited a trend of decrease that was not statistically
significant in the fed state (Figure 3.2A), while the gene expression of Cebpb,
Dbp, and Hnf1a was not affected (Figure 3.2B-E). More importantly, concomitant
deletion of Foxo1 (FoxoDKO) fully restored the decreased Cebpa expression to
control levels (Figure 3.2B). Similarly, liver-specific deletion of Akt1 and Akt2
(AktDKO) had no effect on the expression levels of Cebpb, Dbp, and Hnf1a, but
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led to a significant decrease in Cebpa gene expression (Figure 3.3A-D).
Concomitant deletion of Foxo1 completely restored the decreased Cebpa
expression to control levels in the fasted state, but only partially in the fed state
(Figure 3.3A). These results show that under certain conditions, Cebpa gene
expression exhibits the same pattern as albumin, and both are negatively
correlated with hepatic Foxo1 activity. In addition, there seems to be other
nutrient-dependent, Foxo1-independent pathways that regulate Cebpa
expression.
We then asked whether the gene expression levels of these transcription
factors were differentially regulated in Type 1 diabetic livers as well and whether
Foxo1 activity also contributed to the transcription regulation. To this end, we
used STZ to induce diabetes in either control (GFP) or liver-specific Foxo1
knockout mice (FoxoKO). Surprisingly, STZ treatment did not have any effect on
the gene expression of these transcription factors (Figure 3.4A-D), despite of the
elevated Foxo1 activity. Ablation of Foxo1 also showed no effect, suggesting
that the transcriptional regulation of these genes was independent of Foxo1.
To test whether the decreased Cebpa gene expression correlated with a
decrease in protein level, we measured the hepatic C/EBPα protein levels by
Western blotting. Interestingly, despite of the decreased mRNA levels, C/EBPα
protein remained unchanged in IRKO and AktDKO livers, and concomitant
deletion of Foxo1 in these models had no effect on the C/EBPα protein levels
(Figure 3.5A and Figure 3.6A, respectively). On the contrary, C/EBPβ protein
levels were slightly increased in IRKO and AktDKO livers compared to control,
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and concomitant ablation of Foxo1 in these models normalized the C/EBPβ
protein to control levels (Figure 3.5B and Figure 3.6B, respectively).

C/EBPα activity is negatively correlated with Foxo1 activity in liver
C/EBPα activates its own transcription in a positive feedback loop (Nerlov,
2008). Having observed a decreased Cebpa expression without detectable
changes in C/EBPα protein levels, we hypothesized that C/EBPα activity was
reduced in liver when Foxo1 was constitutively active. To test this idea, we set
out to measure expression levels of the C/EBPα target genes.
11β-hydroxysteroid dehydrogenase type 1 (Hsd11b1) is a direct target
gene of C/EBPα (Inoue et al., 2004; Williams et al., 2000). Interestingly, we
found that Hsd11b1 gene expression was significantly decreased in AktDKO
livers, and concomitant deletion of Foxo1 fully rescued the expression to control
levels (Figure 3.7A). This observation is consistent with the hypothesis that
C/EBPα activity is negatively correlated with Foxo1 activity in the liver. To test
whether C/EBPα activity was also reduced in Type 1 diabetic livers, we
measured Hsd11b1 mRNA level in control and STZ-induced diabetic livers.
Development of diabetes did not affect hepatic Hsd11b1 gene expression,
suggesting that C/EBPα activity was unaffected in these livers. In addition,
deletion of Foxo1 specifically in the liver in either control or STZ-treated mice
exhibited no effect on hepatic Hsd11b1 gene expression (Figure 3.7B). These
results suggest that C/EBPα activity was independent of Foxo1 activity in STZ65

induced Type 1 diabetes model. The discrepancy could be due to differences in
experimental systems used (See Discussion).
We also investigated whether the negative correlation between Foxo1
activity and C/EBPα activity was a general phenomenon for all C/EBPα target
genes or one specific for the regulation of Alb and Hsd11b1. To this end, we first
compiled a list of potential C/EBPα target genes by identifying the overlap
between the C/EBPα ChIP-seq dataset and the list of genes differentially
regulated in Cebpa knockout mice (Jakobsen et al.; Pedersen et al., 2007). We
reasoned that these genes would most likely represent the direct targets of
C/EBPα as their expression levels are C/EBPα-dependent and they have
C/EBPα bound near their transcription start sites. We then measured the mRNA
levels of these identified genes in GFP, AktDKO, and FoxoTKO livers. Most of
these genes exhibited differential expression in AktDKO livers compared to
control. Interestingly, concomitant deletion of Foxo1 (FoxoTKO) completely
restored the altered gene expression back to control levels (Figure 3.7C). These
results supported our hypothesis that it is a general mechanism where
constitutive activation of Foxo1 is correlated with a decrease in C/EBPα activity.

Constitutive activation of Foxo1 is correlated with decreased C/EBPα and
C/EBPβ occupancy at the albumin promoter
Recent studies suggest that Foxo1 directly interacts with C/EBPα in
adipocytes and neonatal liver to modulate C/EBPα activity (Qiao and Shao, 2006;
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Sekine et al., 2007). In addition, Foxo1 has been known to interact with
transcription factors to interfere with their DNA binding (Deng et al., 2012;
Dowell, 2003; Fan et al., 2009). To test whether constitutive activation of Foxo1
interferes with C/EBPα DNA binding at the albumin promoter, we performed
chromatin immunoprecipitation (ChIP) of C/EBPα and C/EBPβ in control,
AktDKO, and FoxoTKO livers. Figure 3.8A shows the C/EBPβ binding peaks
identified by ChIP-seq in wildtype mouse livers at the albumin promoter. Since
C/EBPα and C/EBPβ often bind to DNA as a heterodimer, the peaks were used
to predict C/EBPα binding sites, which were confirmed by ChIP using an antibody
directed against C/EBPα (Figure 3.8B). Interestingly, C/EBPα and C/EBPβ
occupancy at the albumin promoter was reduced in AktDKO livers compared to
controls, and concomitant deletion of Foxo1 specifically in the liver reversed this
decrease (Figure 3.8B and C). This result indicates that Foxo1 activity was
negatively correlated with C/EBPα and C/EBPβ binding to the albumin promoter,
possibly by directly interacting with them and interfering with their DNA binding.
Next, we investigated whether C/EBPα binding to the albumin promoter
was also decreased in diabetic livers. To this end, we injected STZ to induce
Type 1 diabetes in either control or FoxoKO mice and used ChIP to measure
C/EBPα and C/EBPβ occupancy at the albumin promoter. In STZ-induced
diabetic livers, C/EBPα binding to the albumin promoter was decreased
compared to control only at Site 2 (approximately 2.5kb upstream of the
transcription start site, Figure 3.9A). C/EBPβ binding to the albumin promoter, on
the other hand, was increased in STZ-induced diabetic livers compared to control
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(Figure 3.9B). Importantly, ablation of Foxo1 restored all diabetes-induced
changes in C/EBPα and C/EBPβ enrichment (Figure 3.9A and B). Taken
together, these results suggest that development of diabetes alters the binding of
C/EBPα and C/EBPβ to the albumin promoters in a Foxo1-dependent manner.

C/EBPα and C/EBPβ occupancy at the promoter of other Cebpa target genes
Since we observed decreased gene expression of other C/EBPα target
genes such as Cebpa and Hsd11b1 (Figure 3.3A and Figure 3.7A, respectively),
we hypothesized that this is due to decreased C/EBPα binding to the promoter of
these genes as well, and C/EBPα occupancy at these sites would also be
negatively correlated with Foxo1 activity. To test this hypothesis, we first
measured C/EBPα and C/EBPβ occupancy at the promoter of Cebpa (Figure
3.10A) using ChIP. C/EBPα showed a slightly decreased enrichment in AktDKO
livers compared to control, although the difference did not reach statistical
significance. Importantly, concomitant deletion of Foxo1 restored the slight
decrease back to control levels (Figure 3.10B). C/EBPβ binding to the promoter
of Cebpa was not different among GFP, AktDKO, and FoxoTKO livers (Figure
3.10C). Next, we examined the occupancy of C/EBPα and C/EBPβ at the Cebpa
promoter in STZ-induced diabetic livers. C/EBPα binding to the Cebpa promoter
was not affected by the development of Type 1 diabetes (Figure 3.10D). C/EBPβ
occupancy, however, showed an increase in diabetic livers compared to controls.
Furthermore, this increase was abrogated by deletion of Foxo1 specifically in the
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liver (Figure 3.10 E), suggesting that increased binding of C/EBPβ to the Cebpa
promoter was dependent on Foxo1 activity.
We also measured C/EBPα and C/EBPβ occupancy at the Hsd11b1
promoter (Figure 3.11A). Similar to what we observed at the Cebpa promoter,
we found a slight, yet statistically insignificant decrease in C/EBPα occupancy at
the Hsd11b1 promoter in AktDKO livers, which was restored when Foxo1 was
concomitantly deleted (Figure 3.11B). C/EBPβ binding to the Hsd11b1 was
slightly increased in AktDKO livers. However, this increase was independent of
Foxo1 activity, as deletion of Foxo1 showed no effect (Figure 3.11C). In STZinduced diabetic livers, C/EBPα binding to the Hsd11b1 promoter showed no
difference when compared to controls, whereas C/EBPβ exhibited significantly
increased enrichment, which was restored to control levels with the deletion of
Foxo1 (Figure 3.11D and E), suggesting that the increased C/EBPβ binding to
these sites was dependent on Foxo1 activity.

Overexpressing C/EBPα in AktDKO livers to rescue the reduced albumin
expression
Since we observed that the occupancy of C/EBPα at the albumin promoter
directly correlated with albumin gene expression in GFP, AktDKO, and FoxoTKO
livers, we hypothesized that the decreased C/EBPα DNA binding as a result of
the constitutive activation of Foxo1 contributed to the decreased albumin
expression. To test this model, we overexpressed C/EBPα in AktDKO mice to
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see if this could rescue the reduced albumin gene expression. Using an adenoassociated virus, we achieved an approximately 4-fold overexpression of Cebpa
in liver (Figure 3.12B). C/EBPα protein levels were also significantly increased
compared to controls. Notably, overexpressing C/EBPα did not affect hepatic
C/EBPβ protein levels (Figure 3.12A). We also observed increased gene
expression of Hsd11b1 (Figure 3.12B), suggesting that C/EBPα overexpression
led to increased hepatic C/EBPα activity at the Hsd11b1 promoter. However,
C/EBPα overexpression did not improve the circulating albumin level in AktDKO
animals (Figure 3.12C). To our surprise, albumin gene expression was further
decreased in animals overexpressing C/EBPα (Figure 3.12D).
To understand this surprising result, we first assessed the effect of
C/EBPα overexpression on restoring the reduced C/EBPα binding to DNA. We
found that the overexpression failed to increase C/EBPα occupancy at the
promoters of Alb, Cebpa, and Hsd11b1 in AktDKO livers (Figure 3.13A). This is
likely the reason why C/EBPα overexpression failed to rescue the reduced
albumin expression and production in AktDKO livers. In addition, C/EBPβ
occupancy at these sites was significantly decreased as a result of the C/EBPα
overexpression (Figure 3.13B). Since C/EBPβ is also a transcription activator of
albumin, this might explain the further decrease in hepatic albumin mRNA levels.

Discussion
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The Alb promoter does not contain a Foxo1 binding site, suggesting that it
is unlikely for Foxo1 to repress albumin expression directly. In this chapter, we
investigated possible mechanisms by which Foxo1 represses albumin expression
indirectly.
Shp and Id3 are putative transcription repressors downstream of Foxo1
that might play a role in the regulation of albumin expression. Specifically, Shp
has been described to directly interact with C/EBPα and to decrease its
transcriptional activity (Park et al., 2007). Since C/EBPα activates albumin
expression, we hypothesized that the induction of Shp by Foxo1 could potentially
mediate the downregulation of albumin gene expression. Id3 exhibits reciprocal
expressions both in space and in time with albumin during chick liver
development, consistent with it being an inducible repressor for albumin
expression (Nakayama et al., 2006). We found that the gene expression of Shp
and Id3 were elevated in Akt-null livers, where Foxo1 activity was constitutively
high, and concomitant deletion of Foxo1 reversed this induction (Figure 3.1A and
B). The reciprocal relationship between albumin expression and the expression
of Shp and Id3 is consistent with the model where Shp and Id3 repress albumin
transcription downstream of Foxo1. However, the expression patterns of Shp
and Id3 in control animals were inconsistent with the model where Foxo1 induces
these transcription repressors during the fasting state (Figure 3.1 A-C),
suggesting that Foxo1 might not be a physiologic regulator of these genes. In
addition, we did not observe the same relationship in the IRKO mice (Figure
3.1C). The discrepancy between the IRKO and AktDKO models also suggests
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that regulation of Shp and Id3 is more complex and possibly depends on
regulators other than Foxo1. Therefore, repression mediated by Shp and Id3 is
unlikely to be the unifying mechanism of how Foxo1 represses albumin gene
expression.
Since a number of studies have demonstrated that Foxo1 interacts with a
variety of transcription factors to modulate their activity (Christian, 2002; Deng et
al., 2012; Dowell, 2003; Fan et al., 2009; Ramaswamy et al., 2002; Van der Vos
and Coffer, 2008), we then turned our attention to transcription activators known
to regulate albumin and assessed whether this is the mechanism by which Foxo1
exerts its repressive effect on albumin gene expression. Interestingly, under
certain conditions, hepatic expression of Cebpa inversely correlated with Foxo1
activity and consistent with albumin expression. Specifically, in IRKO and
AktDKO livers where Foxo1 was constitutively active, Cebpa exhibited decreased
expression that was completely reversed by concomitant deletion of Foxo1
especially in the fasted state. Since C/EBPα regulates its own transcription, this
observation suggests that C/EBPα activity exhibits a reciprocal relationship with
Foxo1 activity in the liver, consistent with the model in which Foxo1 inhibits the
activity of C/EBPα to mediate the repression of albumin expression. In the fed
state, however, inactivation of Foxo1 was not sufficient to restore the reduced
Cebpa expression in Akt-null livers, suggesting that there are other nutrientdependent, Foxo1-independent pathways that regulate Cebpa expression.
To test the reciprocal relationship between C/EBPα and Foxo1, we
measured the expression of Hsd11b1, a direct target gene of C/EBPα that is
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involved in glucocorticoid synthesis in liver (Inoue et al., 2004; Williams et al.,
2000). Consistent with the observed expression patterns of albumin and Cebpa,
Hsd11b1 also exhibited significantly reduced expression in AktDKO livers that
was reversed when Foxo1 was concomitantly deleted (Figure 3.7A), providing
another piece of supporting evidence that C/EBPα activity was decreased when
Foxo1 activity was constitutively high, and vice versa. We then compiled a list of
genes that are most likely the functional C/EBPα targets by examining the
overlap between genes whose promoters are bound by C/EBPα (C/EBPα ChIP,
(Jakobsen et al.)) and genes with differential expression when Cebpa is deleted
(Cebpa knockout microarray, (Pedersen et al., 2007)). We found that almost all
C/EBPα target genes exhibited differential expression that was dependent on
Foxo1 activity (Figure 3.7C), further validating the model that Foxo1 interferes
with C/EBPα activity.
The decrease in C/EBPα activity in IRKO and AktDKO livers was not due
to a loss of C/EBPα protein, as there was no detectable change in C/EBPα
protein in IRKO and AktDKO livers, and concomitant deletion of Foxo1 in these
livers exhibited no effect on C/EBPα protein levels (Figure 3.5A and Figure 3.6A).
This suggests that decreased C/EBPα activity in IRKO and AktDKO livers was
due to a decrease in the inherent transcription activating activity. Interestingly,
C/EBPβ protein was regulated differently as C/EBPα and was dependent on
Foxo1 activity, as we observed a mild increase in C/EBPβ protein in both IRKO
and AktDKO livers compared to control, and concomitant deletion of Foxo1
completely reversed this increase (Figure 3.5B and Figure 3.6B). These
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observations highlight differential regulations of C/EBPα and C/EBPβ
downstream of Foxo1: C/EBPα seems to be regulated at the level of
transcription, while C/EBPβ is regulated post-transcriptionally at the protein level
either by translation or degradation.
Recent studies have revealed that Foxo1 can modulate gene expression
independent of DNA-binding by associating with a variety of transcription factors
(Christian, 2002; Deng et al., 2012; Dowell, 2003; Fan et al., 2009; Hirota et al.,
2008; Ramaswamy et al., 2002; Van der Vos and Coffer, 2008). For instance,
identified from a yeast two-hybrid screen, Foxo1 physically interacts with
peroxisome proliferator-activated receptor γ (PPARγ) and disrupts PPARγ’s
DNA-binding to antagonize its activity (Dowell, 2003). Recently, Deng et al.
found that Foxo1 inhibits SREBP-1c transcription by disrupting the assembly of
the transcriptional complex at the Srebp1c promoter (Deng et al., 2012). In
addition, it has been shown that Foxo1 physically interacts with C/EBPα in
adipocytes and neonatal liver (Qiao and Shao, 2006; Sekine et al., 2007).
Collectively, these studies led us to speculate that Foxo1 may antagonize
C/EBPα activity by directly interacting with C/EBPα and interfering with its DNA
binding.
To assess C/EBPα binding to the albumin promoter, we performed
chromatin immunoprecipitation in control, AktDKO, and FoxoTKO livers using an
antibody targeted specifically at C/EBPα. We found that C/EBPα occupancy at
the albumin promoter was decreased in AktDKO livers compared to control,
especially at the proximal promoter region (approximately 2.5kb upstream from
74

the transcription start site). Moreover, concomitant deletion of Foxo1 restored
the decreased occupancy to control level (Figure 3.8B). This observation is
consistent with our hypothesis that constitutively active Foxo1 may interfere with
C/EBPα’s binding to DNA and thus lead to repression of the albumin gene. We
also observed a decrease in C/EBPβ occupancy at the albumin promoter (Figure
3.8C). It is possible that C/EBPβ binding to the albumin promoter was decreased
as a result of disrupted C/EBPα binding, since these factors often bind to DNA as
a heterodimer. Interestingly, C/EBPα and C/EBPβ occupancy did not exhibit the
same pattern at the distal promoter region (site 4, approximately 30kb upstream
from the transcription start site), suggesting that at this site, C/EBPα and C/EBPβ
interacted with the promoter as homodimers rather than a heterodimer: DNAbinding of C/EBPα homodimer at this site was disrupted by Foxo1, whereas that
of C/EBPβ homodimer was unaffected.
We also examined the occupancy of C/EBPα and C/EBPβ at the
promoters of Cebpa and Hsd11b1 in control, AktDKO, and FoxoTKO livers.
Constitutively active Foxo1 in AktDKO livers was correlated to a slight, yet
statistically insignificant, decrease in C/EBPα DNA binding to the promoters of
these genes. Nevertheless, concomitant deletion of Foxo1 still restored the slight
decrease to control levels, suggesting that C/EBPα occupancy was dependent
on Foxo1 (Figure 3.10B and Figure 3.11B). On the contrary, C/EBPβ binding to
these promoters was unaffected by Foxo1 activity level (Figure 3.10C and Figure
3.11C). Such disconnect between C/EBPα and C/EBPβ occupancy could be
explained by the possibility that C/EBPα and C/EBPβ interacted with these sites
75

as homodimers exclusively, and Foxo1 only interfered with C/EBPα binding.
Since gene expression for both Cebpa and Hsd11b1 was significantly decreased
in AktDKO livers without a significant decrease in C/EBPα occupancy at the
promoter, it is likely that other factors contributed to the repression of these
genes as well.
To directly investigate the role of C/EBPα and test whether reduced
C/EBPα occupancy is a major contributing factor for decreased albumin gene
expression, we overexpressed C/EBPα in AktDKO livers in an attempt to rescue
the decreased C/EBPα occupancy to see if that is sufficient to restore albumin
production. Using an adeno-associated virus, we achieved a 4-fold
overexpression in Cebpa mRNA, and C/EBPα protein levels were significantly
increased compared to controls (Figure 3.12A and B). Hsd11b1 gene expression
also significantly increased, suggesting that C/EBPα activity was elevated in
these livers as a result of the overexpression (Figure 3.12B). Importantly,
C/EBPα overexpression exhibited no effect on C/EBPβ gene expression and
protein levels in AktDKO livers (Figure 3.12A and B). C/EBPα overexpression in
AktDKO livers did not improve total serum protein concentration in these animals
(Figure 3.12C). Opposite to what we expected, C/EBPα overexpression actually
exacerbated the already decreased albumin gene expression in AktDKO livers
(Figure 3.12D). Chromatin immunoprecipitation against C/EBPα revealed that
despite of the increased protein levels, C/EBPα occupancy at the promoters of
albumin, Cebpa, and Hsd11b1 did not increase as a result of the overexpression
(Figure 3.13A). Thus, it remains inconclusive whether decreased C/EBPα
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binding to the albumin promoter is the major contributing factor for decreased
albumin expression in AktDKO livers. It is also interesting to note that even
though C/EBPα occupancy at the Hsd11b1 promoter was not rescued in Cebpaoverexpressing livers, Hsd11b1 expression was nonetheless elevated,
suggesting that increased DNA-binding might not be the only mechanism
C/EBPα has to activate gene expression. Interestingly, C/EBPβ binding to the
promoters of albumin, Cebpa, and Hsd11b1 was significantly decreased as a
result of Cebpa overexpression (Figure 3.13B), possibly due to the distorted
stoichiometric ratio of C/EBPα and C/EBPβ in these livers. Since C/EBPβ is also
a transcription activator of albumin expression, loss of C/EBPβ at the promoter of
albumin could potentially contribute to the additional decrease in albumin
expression in Cebpa-overexpressing AktDKO livers.
It is not clear why overexpressing Cebpa in AktDKO livers failed to restore
the decreased C/EBPα occupancy at the albumin promoter. One possibility is
that C/EBPα binding sites become inaccessible when Akt is deleted in the liver.
This could be caused by altered chromatin structure. A recent study by Lee et al.
demonstrates that Akt activity is correlated with histone acetylation level, which is
known to regulate chromatin structure (Lee et al., 2014). In Akt-null liver, histone
acetylation level is likely low and the chromatin is likely more compact, which
could contribute to reduced binding of C/EBPα. Alternatively, it is possible that
C/EBPα binding to the albumin promoter requires a cofactor that becomes
downregulated in Akt-null liver. The third possibility is that C/EBPα binding sites
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could be occupied by another transcription factor that is upregulated in Akt-null
liver. The nature of these factors, however, is currently elusive.
As previous discussed, site 2 of the albumin promoter was most likely
occupied by C/EBP α/β heterodimers, since the DNA binding of both factors was
disrupted concomitantly (Figure 3.8B and C). Instead of restoring the decreased
occupancy of C/EBP α/β heterodimers at these sites, Cebpa overexpression
increased the relative C/EBPα to C/EBPβ ratio in the cell and possibly led to a
displacement of C/EBPβ, as suggested by the decrease in C/EBPβ occupancy
(Figure 3.13A and B). As a result, this site likely became occupied by C/EBP α/α
homodimers. Similarly, site 4 of the albumin promoter was possibly occupied by
C/EBP α/α and C/EBP β/β homodimers, as only the occupancy of C/EBPα was
dependent on Foxo1 activity but not that of C/EBPβ (Figure 3.8B and C). We
speculate that Cebpa overexpression displaced C/EBPβ, resulting in a loss of
C/EBP β/β homodimers at this site.
Sequential ChIP assay could be useful here to directly test the relative
protein dimeric states at these sites. Specifically, C/EBPα ChIP samples would
be re-ChIPed by the C/EBPβ antibody. By comparing the relative enrichment
from first ChIP with that from the second ChIP, one may gain insights on the
nature of the dimer occupying that particular site: A site bound by C/EBP α/β
heterodimer would exhibit preserved enrichment after re-ChIP with C/EBPβ
antibody, whereas a site bound by C/EBP α/α homodimer would lose enrichment
after C/EBPβ re-ChIP. The reverse order - C/EBPβ ChIP followed by C/EBPα
ChIP - could be used to test occupancy by C/EBP β/β homodimers. This
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experimental system would also be useful to assess the effect of over-expressing
Cebpa on the C/EBP dimeric states.
We did not observe similar effects in the STZ-induced Type 1 diabetic
model. C/EBPα binding to the albumin promoter was only reduced at the
proximal site, but not at the distal site as a result of diabetes (Figure 3.9A).
Interestingly, STZ treatment led to a significant increase in C/EBPβ occupancy,
and deletion of Foxo1 completely reversed this increase, suggesting that the
enhanced C/EBPβ binding to the albumin promoter was dependent on Foxo1
activity (Figure 3.9B). Similar trend was also observed at the Cebpa and
Hsd11b1 promoters, where STZ treatment did not affect C/EBPα binding, but
constitutive activation of Foxo1 was correlated with enhanced C/EBPβ binding at
these sites (Figure 3.10D and E, Figure 3.11D and E). C/EBPβ exits as two
isoforms: one activating and one inhibitory (Nerlov, 2007; 2008). The C/EBPβ
antibody we used in ChIP experiments does not differentiate the two isoforms.
Therefore, it is possible that the occupancy of the inhibitory C/EBPβ isoform was
increased in STZ-treated livers, thus causing a decrease in albumin gene
expression. The specific C/EBPβ isoform recruited to the albumin promoter in
this model requires further characterization.
The discrepancy between the STZ-induced Type 1 diabetes model and
the liver-specific genetic knockout model may be explained by either the genetic
strain differences of the animals used in this study, or the drastic physiological
differences between the two animal models. Although liver-specific Ir knockout
and liver-specific Akt1/Akt2 double-knockout animals develop peripheral insulin
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resistance (Lu et al., 2012), the metabolic defect originated from the liver. On the
other hand, β-cell death following the STZ treatment leads to a systemic defect
that affects all insulin-responsive organs, including liver, adipose, muscle, and
brain. As a result, the severity of the metabolic defects is much higher in the
STZ-induced diabetes model, as indicated by their outrageously high blood
glucose level as well as the significant loss of body mass. It is thus difficult to deconvolute the liver-specific mechanism that regulates albumin expression using
the STZ-induced diabetes model.
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Figure 3.1: Shp and Id3 are unlikely to be the transcriptional repressors
downstream of Foxo1 to repress albumin expression.
A,B. Hepatic gene expression level of small heterodimer partner (Shp, A) and
inhibitor of DNA binding 3 (Id3, B) in GFP control (GFP), liver-specific Akt1/Akt2
double-knockout (AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout
(FoxoTKO) animals that had been either fasted overnight or fasted overnight and
refed for 4 hours. n = 3-4; ns, not significant, **p<0.01 vs. GFP, and ***p<0.001
vs. GFP by two-way ANOVA using Sidak post-test.
C,D. Hepatic gene expression level of Shp (C) and Id3 (D) in GFP, liver-specific
Ir knockout (IRKO), and liver-specific Ir/Foxo1 double-knockout (FoxoDKO)
animals that had been either fasted overnight or fasted overnight and refed for 4
hours. n = 5-7; ns, not significant, *p<0.0.5 vs. GFP by two-way ANOVA using
Sidak post-test.
E,F. Hepatic gene expression level of Shp (E) and Id3 (F) in GFP and liverspecific Foxo1 knockout (FoxoKO) animals 9 days post an intra-peritoneal
injection of either buffer (Ctrl) or streptozotocin (STZ) at 200mg per kg body
weight. n = 5-7.
All values are expressed as mean ± SEM.
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Figure 3.2: Hepatic expression of transcription factors known to regulate
albumin expression in liver-specific Ir knockout (IRKO) and liver-specific
Ir/Foxo1 double-knockout (FoxoDKO) mice.
A. Diagram of Alb promoter showing transcription factors that activate albumin
expression and their respective binding sites. Cebpa/b, CCAAT/enhancer
binding protein a/b; Hnf1a, hepatic nuclear factor 1a; Nfy, nuclear factor Y; Dbp,
D box binding protein; Nf1, neurofibromatosis factor 1.
B-E. Hepatic gene expression of Cebpa (B), Cebpb (C), Dbp (D), and Hnf1a (E)
in GFP control (GFP), IRKO, and FoxoDKO animals that had been either fasted
overnight or fasted overnight and refed for 4 hours.
All values are expressed as mean ± SEM. n = 5-9; ns, not significant; *p<0.05
vs. GFP by two-way ANOVA using Sidak post-test.
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Figure 3.3: Hepatic expression of transcription factors known to regulate
albumin expression in liver-specific Akt1/Akt2 double-knockout (AktDKO)
and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO) mice.
Hepatic gene expression of CCAAT/enhancer binding protein a (Cebpa, A),
Cebpb (B), D box binding protein (Dbp, C), and hepatic nuclear factor 1a (Hnf1a,
D) in GFP control (GFP), AktDKO, and FoxoTKO animals that had been either
fasted overnight or fasted overnight and refed for 4 hours.
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All values are expressed as mean ± SEM. n = 3-4; ns, not significant, **p<0.01
vs. GFP, and ***p<0.001 vs. GFP by two-way ANOVA using Sidak post-test.
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Figure 3.4: Hepatic expression of transcription factors known to regulate
albumin expression in Type 1 diabetic livers.
Hepatic gene expression of CCAAT/enhancer binding protein a (Cebpa, A),
Cebpb (B), D box binding protein (Dbp, C), and hepatic nuclear factor 1a (Hnf1a,
D) in GFP control (GFP) and liver-specific Foxo1 knockout (FoxoKO) animals 9
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days post an intra-peritoneal injection of either buffer (Ctrl) or streptozotocin
(STZ) at 200mg per kg body weight.
All values are expressed as mean ± SEM.
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Figure 3.5: Hepatic C/EBPα and C/EBPβ protein levels in liver-specific Ir
knockout (IRKO) and liver-specific Ir/Foxo1 double-knockout (FoxoDKO)
mice.
Western blots for C/EBPα (A), C/EBPβ (B), and actin in liver homogenates of
GFP control (GFP), IRKO, and FoxoDKO animals.
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Figure 3.6: Hepatic C/EBPα and C/EBPβ protein levels in liver-specific
Akt1/Akt2 double-knockout (AktDKO) and liver-specific Akt1/Akt2/Foxo1
triple-knockout (FoxoTKO) mice.
Western blots for C/EBPα (A), C/EBPβ (B), and actin in liver homogenates of
GFP control (GFP), AktDKO, and FoxoTKO animals.
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Figure 3.7: C/EBPα target genes exhibit differential expression in Akt-null
livers that is restored by additional deletion of Foxo1.
A. Hepatic Hsd11b1 mRNA level in GFP control (GFP), liver-specific Akt1/Akt2
double knockout (AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout
(FoxoTKO) animals. n = 3-4; ns, not significant, and ***p<0.001 vs. GFP by oneway ANOVA using Sidak post-test.
B. Hepatic Hsd11b1 mRNA in GFP and liver-specific Foxo1 knockout (FoxoKO)
animals 9 days post an intra-peritoneal injection of either buffer (Ctrl) or
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streptozotocin (STZ) at 200mg per kg body weight. n = 5-7; ns, not significant by
two-way ANOVA using Sidak post-test.
C. Hepatic mRNA levels of other putative target genes of C/EBPα in GFP,
AktDKO, and FoxoTKO animals. Apob, apolipoprotein B; Apoc3, apolipoprotein
C-III; Saa4, serum amyloid A4; Cps1, carbamoyl-phosphate synthetase 1; Alas2,
aminolevulinic acid synthase 2; Cd1d1, CD1d1 antigen; Mrap, melanocortin 2
receptor accessory protein; Prlr, prolactin receptor; Fgf1, fibroblast growth factor
1; Smpd3, sphingomyelin phosphodiesterase 3; Fgfr2, fibroblast growth factor
receptor 2; Sulf2, sulfatase 2; Tgfbr2, transforming growth factor, beta receptor II.
n = 3-4; ns, not significant, *p<0.05 vs. GFP, **p<0.01 vs. GFP, and ***p<0.001
vs. GFP by two-way ANOVA using Sidak post-test.
All values are expressed as mean ± SEM.
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Figure 3.8: C/EBPα and C/EBPβ binding to the albumin promoter negatively
correlates with hepatic Foxo1 activity.
A. ChIP-seq profile for C/EBPβ at the albumin promoter. C/EBPβ binding sites
selected for analyzing C/EBPα and C/EBPβ enrichment are indicated.
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B, C. Hepatic enrichment of C/EBPα (A) and C/EBPβ (B) at indicated sites of the
albumin promoter in GFP control (GFP), liver-specific Akt1/Akt2 double-knockout
(AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO) animals.
Ins serves as a negative control site not bound by C/EBPα.
All values are expressed as mean ± SEM. n = 3-4; **p<0.01 vs. GFP by one-way
ANOVA using Sidak post-test.
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Figure 3.9: C/EBPα and C/EBPβ binding to the albumin promoter in diabetic
liver.
Hepatic enrichment of C/EBPα (A) and C/EBPβ (B) at indicated sites (See Figure
3.10A) of the albumin promoter in GFP control (GFP) and liver-specific Foxo1
knockout (FoxoKO) animals 9 days post an intra-peritoneal injection of either
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buffer (Ctrl) or streptozotocin (STZ) at 200mg per kg body weight. Ins and Arbp
serve as negative control sites not bound by C/EBPα.
All values are expressed as mean ± SEM. n = 3; **p<0.01 vs. GFP+Ctrl, and
***p<0.001 vs. GFP+Ctrl by two-way ANOVA using Sidak post-test.
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Figure 3.10: C/EBPα and C/EBPβ binding to the Cebpa promoter.
A. ChIP-seq profile for C/EBPβ at the Cebpa promoter. C/EBPβ binding sites
selected for analyzing C/EBPα and C/EBPβ enrichment are indicated.
B,C. Hepatic enrichment of C/EBPα (B) and C/EBPβ (C) at indicated sites of the
Cebpa promoter in GFP control (GFP), liver-specific Akt1/Akt2 double-knockout
(AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO) animals.
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D,E. Hepatic enrichment of C/EBPα (C) and C/EBPβ (D) at indicated sites of the
Cebpa promoter in GFP and liver-specific Foxo1 knockout (FoxoKO) animals 9
days post an intra-peritoneal injection of either buffer (Ctrl) or streptozotocin
(STZ) at 200mg per kg body weight.
All values are expressed as mean ± SEM. n = 3-4; ***p<0.001 vs. GFP+Ctrl by
two-way ANOVA using Sidak post-test.
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Figure 3.11: C/EBPα and C/EBPβ binding to the Hsd11b1 promoter.
A. ChIP-seq profile for C/EBPβ at the Hsd11b1 promoter. C/EBPβ binding sites
selected for analyzing C/EBPα and C/EBPβ enrichment are indicated.
B,C. Hepatic enrichment of C/EBPα (B) and C/EBPβ (C) at the indicated sites of
the Hsd11b1 promoter in GFP control (GFP), liver-specific Akt1/Akt2 doubleknockout (AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout
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(FoxoTKO) animals. n = 3; N.A., not available, and *p<0.05 vs. GFP by two-way
ANOVA using Sidak post-test.
D,E. Hepatic enrichment of C/EBPα (D) and C/EBPβ (E) at indicated sites of the
Hsd11b1 promoter in GFP and liver-specific Foxo1 knockout (FoxoKO) animals 9
days post an intra-peritoneal injection of either buffer (Ctrl) or streptozotocin
(STZ) at 200mg per kg body weight. n = 3; N.A., not available, and ***p<0.001
vs. GFP+Ctrl by two-way ANOVA using Sidak post-test.
All values are expressed as mean ± SEM.
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Figure 3.12: Overexpression of Cebpa in liver-specific Akt1/Akt2 doubleknockout (AktDKO) animals fails to rescue the reduced albumin
production.
A. Western blots for C/EBPα and C/EBPβ in liver homogenates of AktDKO
animals that either do (AAV-C/EBPα) or do not (AAV-GFP) overexpress Cebpa.
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B-D. Hepatic gene expression of Cebpa, Cebpb, and Hsd11b1 (B), serum protein
concentration (C), and hepatic albumin mRNA level (D) in AktDKO animals that
either do or do not overexpress Cebpa.
All values are expressed as mean ± SEM. n = 2-3; ns, not significant, *p<0.05
vs. AktDKO+AAV-GFP, **p<0.01 vs. AktDKO+AAV-GFP, and ***p<0.001 vs.
AktDKO+AAV-GFP by two-tailed Student’s t-test.
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Figure 3.13: Overexpression of Cebpa in liver-specific Akt1/Akt2 doubleknockout (AktDKO) animals fails to rescue the reduced C/EBPα binding to
the albumin promoter and further decreases C/EBPβ occupancy.
Hepatic enrichment of C/EBPα (A) and C/EBPβ (B) at indicated sites of the Alb,
Cebpa, and Hsd11b1 promoters (See Figure 3.9A, Figure 3.11A, and Figure
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3.12A) in AktDKO animals that either do (AktDKO+AAV-C/EBPα) or do not
(AktDKO+AAV-GFP) overexpress Cebpa. Ins serves as a negative control site
not bound by C/EBPα.
All values are expressed as mean ± SD. n = 2; N.A., not available, *p<0.05 vs.
AktDKO+AAV-GFP, **p<0.01 vs. AktDKO+AAV-GFP
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Insulin stimulates albumin transcription by inhibiting Foxo1
The effects of insulin on carbohydrate and lipid metabolism have been
extensively characterized, but how insulin regulates protein metabolism remains
largely unknown (Kimball et al., 1994; Tessari et al., 2011). Although it has been
almost 30 years since it was first demonstrated that insulin controls serum
albumin production in liver by stimulating albumin transcription (Lloyd et al.,
1987), the detailed pathway has not been elucidated until the present study.
Using liver-specific knockout models, we found that insulin signals directly on the
liver through Akt to phosphorylate and inhibit Foxo1, which functions as a
transcription repressor of the albumin gene. We also found that chronic
activation of hepatic Foxo1 in Type 1 diabetic subjects is causal for the
hypoalbuminemia phenotype in these individuals.
We speculate that this regulatory mechanism of insulin was evolved to
limit nonessential biosynthesis during metabolic stress. Albumin mRNA and
protein have a long half-life and therefore do not change with normal fasting and
feeding, but decrease during diabetes and prolonged starvation. Under these
conditions, nutrients for energy generation to sustain survival become extremely
limited. Since that albumin is synthesized at a high rate (12-25 grams per day in
a young healthy adult) (Fanali et al., 2012), it is essential to efficiently turn off its
production to preserve the limited amino acids during an extended fast, and the
most effective way to achieve this would be to reduce the level of mRNA
message.
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Foxo1 is a transcriptional repressor of the Alb gene
There still remains considerable uncertainty about the mechanism by
which Foxo1 functions as a repressor of the albumin gene. Previous works have
shown that the DNA-binding domain of Foxo is not required for Foxo to mediate
gene repression, suggesting an indirect mechanism (Murphy et al., 2003;
Schuster et al., 2010; Tepper et al., 2013). A recent study in C. elegans
described PQM-1 as a transcription activator that exhibits reciprocal cellular
localization as Foxo1, thereby presenting a possible mechanism in which Foxo1
activation leads to the nuclear exclusion of PQM-1 and subsequent gene
downregulation (Tepper et al., 2013). However, it is not clear whether an
orthologous mechanism exists in mammalian systems. Here, we propose three
indirect mechanisms by which Foxo1 represses albumin gene expression: 1) by
modulating the activity of another transcription factor via direct protein-protein
interaction; 2) by inducing the expression of a transcriptional repressor; and 3) by
mediating a metabolic change in the cell.

Foxo1 as a repressor via direct protein-protein interaction
Previous studies have extensively characterized the transcriptional
regulation of Alb and identified C/EBPα, C/EBPβ, Hnf-1α, and Dbp as several
liver-enriched transcription factors that stimulate albumin gene expression
(Lichtsteiner et al., 1987; Maire et al., 1989). Our results show that Foxo1 activity
is inversely correlated with the occupancy level of C/EBPα at the albumin
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promoter. Although we did not perform co-immunoprecipitation experiments to
directly demonstrate that Foxo1 and C/EBPα physically interact with each other,
previous experimental data from other studies in adipocytes and neonatal liver
suggests that such interaction is very likely (Qiao and Shao, 2006; Sekine et al.,
2007). Given these data, we speculate that in the absence of insulin signaling,
Foxo1 is nuclear and directly binds to C/EBPα; the interaction between C/EBPα
and Foxo1 decreases C/EBPα binding to the albumin promoter, and thus
downregulates albumin gene expression. This model is further supported by
other examples in literature where Foxo1 directly interacts with transcription
factors to inhibit their DNA binding (Christian, 2002; Deng et al., 2012; Dowell,
2003; Fan et al., 2009; Hirota et al., 2008; Ramaswamy et al., 2002; Van der Vos
and Coffer, 2008). Taken together, this could indeed be the mechanism by
which Foxo1 acts as a repressor for albumin transcription. It is important to note,
however, that in the present study, we only examined how Foxo1 influences the
DNA binding of C/EBPs. It is entirely possible that in addition to these
transcription factors, Foxo1 also binds to and interferes with other transcription
activators that regulate albumin gene expression.

Foxo1 as a repressor by inducing an intermediate repressor
In addition to regulating the transcription of insulin-responsive genes such
as gluconeogenic enzymes, Foxo1 also regulates the expression of other
transcription factors. Thus, it is possible that Foxo1 represses gene expression
by inducing the expression of an intermediate repressor. Although no repressor
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for albumin gene expression has been described to date, we found that Shp and
Id3, repressors induced by Foxo1, may play a role in albumin gene regulation
(Nakayama et al., 2006; Shin et al., 2012). We tested whether Shp and Id3 could
mediate albumin gene repression downstream of Foxo1 in our models and found
contradictory results. Specifically, while Shp and Id3 were induced in Aktdeficient livers in a Foxo1-dependent manner, this pattern was not observed in
IR-deficient livers. This inconsistency suggests that regulation of Shp and Id3 is
more complex and might involve factors other than Foxo1. Since albumin gene
expression was decreased in both Akt-deficient and IR-deficient livers, it is
unlikely that induction of Shp and Id3 was the mediator for albumin gene
repression downstream of Foxo1. Additional studies might be necessary to
determine whether other transcription repressors act downstream of Foxo1 to
repress albumin expression.

Foxo1 as a repressor by mediating metabolic changes
Albumin expression in STZ-induced Type 1 diabetic mice was also
decreased, and liver-specific deletion of Foxo1 was sufficient to restore albumin
expression to control levels in these mice. However, the mechanism by which
Foxo1 represses albumin gene expression in this model was not immediately
clear. Despite of the high Foxo1 activity, C/EBPα binding to the Alb promoter
was unaffected, indicating that the reduction in albumin expression was not
caused by decreased C/EBPα activity at the promoter. The discrepancy between
this model and the liver-specific knockout models could be due to genetic strain
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variation: we used mice of mixed background for the STZ studies, and our liverspecific knockout model mice were of pure Bl6 background. In addition, the
discrepancy is most likely caused by different pathogenesis of diabetes in these
two models. STZ injection leads to β-cell death and therefore completely
obliterates whole-body insulin signaling. In the liver-specific knockout models, on
the other hand, disruption of insulin signaling originates specifically in the liver,
and insulin resistance is subsequently developed in peripheral tissues. STZinduced Type 1 diabetes represents a more severe and systemic disruption of
metabolic homeostasis, thus it is challenging to determine the liver-specific
mechanism of how Foxo1 represses albumin expression using this model.
Regardless, there must be a mechanism that explains our observation that
albumin expression was inversely correlated with Foxo1 activity in STZ-induced
Type 1 diabetic liver. One possibility is that the normalization of albumin
transcription is downstream of the metabolic effects of inhibiting Foxo1.
Numerous studies have shown that antagonizing or reducing hepatic Foxo1 in
insulin resistant mice can significantly improve glucose tolerance and insulin
action (Altomonte et al., 2003; Dong et al., 2008; Lu et al., 2012; Matsumoto,
2006; Matsumoto et al., 2007; Samuel et al.). For instance, earlier work from our
laboratory shows that concomitant liver-specific deletion of Foxo1 normalizes the
metabolic defects observed in mice with Akt-deficient liver (Lu et al., 2012). We
speculate that defective albumin gene expression in STZ-induced diabetic liver
may be normalized as a result of the improved metabolic homeostasis.
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Foxo1 inhibition normalizes glucose utilization in the liver, possibly by
increasing the expression of glucose kinase (Gck) and/or decreasing the
expression of pyruvate dehydrogenase kinase 4 (Pdk4) (O-Sullivan et al., 2015).
Gck catalyzes the first step of the glycolytic pathway, where dietary glucose
becomes phosphorylated and retained inside the hepatocytes. Pdk4
phosphorylates and inhibits pyruvate dehydrogenase (Pdh), which converts
pyruvate to acetyl-CoA, a key enzymatic step to shuttle carbohydrate into the
citric acid cycle for lipid synthesis or energy generation. Therefore, inhibition of
Foxo1 would lead to increased flux through the glycolytic pathway and the citric
acid cycle, generating more energy and/or acetyl-coA in the cell. Increased
energy charge in liver would alter activities of energy-sensing pathways such as
AMP-activated protein kinase (AMPK) and cAMP responsive element binding
protein (CREB), leading to transcriptional changes. In addition to energy
generation and lipid synthesis, acetyl-CoA is also used to modify lysine residues
of proteins, including transcription factors and histones. Acetylation of
transcription factors has been shown to regulate their activity (Park et al., 2015).
Histone acetylation is sensitive to cellular metabolism and plays an important role
in gene regulation as well (Grunstein, 1997; Wellen et al., 2009). It is thus
conceivable that either increased ATP or higher level of acetyl-CoA in
hepatocytes could induce albumin gene expression.

Hepatic autophagy contributes to serum albumin production
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Autophagy is an important quality control process that degrades and
recycles damaged cellular proteins and organelles. In addition to its
housekeeping role, autophagy also maintains metabolic homeostasis in various
tissues and serves as a significant source of biosynthetic substrates and energy
during metabolic stress (Kim and Lee, 2014; Rabinowitz and White, 2010;
Yamada and Singh, 2012). In liver, insulin signaling turns off autophagy by
activating mTORC1, which inhibits autophagy (Kim and Lee, 2014). Autophagy
also modulates insulin action: suppressing autophagy impairs insulin signaling
and inducing hepatic autophagy can increase insulin sensitivity in the liver (Yang
et al., 2010). To our surprise, we found that hepatic autophagy, a catabolic
process, positively contributes to serum albumin biosynthesis and secretion.
Disrupting hepatic autophagy leads to a decrease in serum albumin level in
overnight-fasted animals. In addition, autophagy can maintain some level of
albumin production in livers with impaired Akt and mTORC1 activity.
Contribution of autophagy on serum albumin production occurs at a post
transcription site. We speculate that autophagy supports albumin protein
translation by supplying amino acids and/or energy generated from autophagic
degradation. In addition, recent data suggests that co-localization of
autophagosomes and mTORC1 facilitates the synthesis and secretion of proteins
(Narita et al., 2011). Based on this observation, it is possible that hepatic
autophagy also contributes to serum albumin production by augmenting its
secretion. A pulse-chase experiment would be helpful to directly address
whether autophagy contributes to albumin secretion. Incorporation of puromycin,
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an aminoacylated-tRNA analog, into nascent peptide chain is a method
alternative to radioactive amino acid labeling to study protein synthesis (Schmidt
et al., 2009). Present at very low concentration (10µg/ml), puromycin does not
inhibit protein synthesis and its incorporation is conveniently detected by
immunoblotting. To measure albumin secretion in AktDKO and Atg5TKO
hepatocytes, I will incubate the cells with puromycin for 10 minutes, followed by a
90-minute chase. At each time point within the chase period, albumin in the
culture media will be immunoprecipiated, and levels of puromycin incorporation
into albumin will be analyzed by western blot. If the appearance rate of
puromycin-containing albumin in the media is decreased in Atg5TKO
hepatocytes, then it suggests autophagy augments the secretory capacity of
hepatocytes to contribute to protein production.

Serum albumin production is intact in Type 2 diabetes
Using our liver-specific knockout models, we found that albumin
transcription is significantly reduced when insulin signaling is disrupted in the
liver. It is important to recognize that in these models, insulin signaling is
completely absent and is therefore not fully representative of Type 2 diabetic
livers, where insulin action is impaired. To assess how albumin transcription is
affected in insulin resistant livers, we measured serum albumin level and hepatic
Alb mRNA in leptin-deficient (ob/ob) mice, a common model for obesity and Type
2 diabetes. We found that unlike what we observed in liver-specific knockout
models, serum albumin transcription and secretion are completely normal in
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ob/ob mice. Consistent with our observation, an earlier study also showed that
serum albumin production is normal in Type 2 diabetic patients (Tessari et al.,
2006b). Taken together, we conclude that regulation of serum albumin
production by insulin is intact in Type 2 diabetes despite of the hepatic insulin
resistance.
Type 2 diabetic patients exhibit the “classic triad” of hyperinsunlinemia,
hyperglycemia, and hypertriglyceridemia. However, this triad of metabolic
defects breaks down when insulin signaling is disrupted at the insulin receptor
level (Michael et al., 2000). This apparent paradox is explained by the dual
action of insulin in the liver: insulin suppresses glucose production by
phosphorylating and inhibition Foxo1, which induce the expression of key
gluconeogenic enzymes; insulin also activates hepatic lipogenesis to increase
lipid synthesis and secretion. To explain the simultaneous elevation of glucose
and lipid production in liver in Type 2 diabetes, Brown and Goldstein suggested a
model of “selective insulin resistance”, where insulin is unable to inhibit Foxo1 to
suppress gluconeogenesis but continues to sustain lipogenesis (Brown and
Goldstein, 2008). However, if this model is correct, Foxo1 should remain active
in leptin-deficient mice, and should thus repress albumin expression. Since we
found that albumin expression in these animals was normal, our data does not
support the hepatic selective insulin resistance model.
In an alternative view, Otero and colleagues suggested that the primary
phenotypic driver for Type 2 diabetes is altered substrate delivery to the liver and
hepatic nutrient handling, and not impaired insulin action per se
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(Otero et al., 2014). This model is supported by experimental evidence indicating
that failure of insulin to suppress gluconeogenesis in liver is driven by substrate
uptake and not gene expression (Catchpole et al., 2007; Edgerton et al., 2009;
Ramnanan et al., 2010; Shawn C Burgess, 2007). In this model, insulinmediated Foxo1 inhibition is likely intact in Type 2 diabetes, which is consistent
with our observation that albumin expression is normal in ob/ob animals.
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Animals
All experiments were performed in male mice that were 10-12 weeks of
age. The IrloxP/loxP, IrloxP/loxP ; Foxo1loxP/loxP, Akt1loxP/loxP ; Akt2loxP/loxP, Akt1loxP/loxP ;
Akt2loxP/loxP ; Foxo1loxP/loxP, and Foxo1loxP/loxP mice have been described previously
(Leavens and Birnbaum, 2011; Matsumoto, 2006; Michael et al., 2000). To
generate liver-specific knockouts, an adeno-associated virus expressing either
GFP or Cre recombinase driven by the promoter of liver-specific gene thyroxine
binding globulin (TBG) was injected into the above mice at 8-10 weeks of age (1
x 1011 genomic copies per mouse). Experiments were performed 2 weeks post
virus injection. For fasting-refeeding experiments, mice were deprived of food for
16 hours (4pm to 9am). The fasted group was sacrificed at 9am, and the refed
group was fed ad libitum for 4 hours with normal chow (Laboratory Rodent Diet,
Cat. 5001) before sacrifice. All animal experiments were reviewed and approved
by the University of Pennsylvania Institutional Animal Care and Use Committee
in accordance with NIH guidelines.

Liver lysates/nuclear extract extraction and Western blotting
Post sacrifice, livers were dissected, freeze-clamped, and stored at -80°C.
Whole cell lysates were prepared by homogenizing frozen liver samples in RIPA
buffer (150 mM NaCl, 50 mM Tris, pH 7.6, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, supplemented with protease and phosphatase
inhibitors). To detect Foxo1, liver nuclear extracts were prepared using the NE117

PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, Cat.
78833). Cleared lysates and nuclear extracts were resolved by SDS-PAGE (1012% acrylamide gel, constant voltage of 100V), transferred onto nitrocellulose
membranes, probed with various antibodies (IR, Cell Signaling, Cat. 3025S;
Foxo1, Cell Signaling, Cat. 9454S; Akt1, Cell Signaling, Cat. 2967; Akt2, Cell
Signaling, Cat. 2964S; Actin, Abcam, Cat. ab6276) and visualized with either
IRDye secondary antibodies (LI-COR Biosciences, Cat. 926-32213 and 92668022) or ECL Western blotting detection reagents (Thermo Scientific, Cat.
32106).

Primary hepatocytes isolation and in vitro albumin secretion assay
Primary hepatocytes were isolated as previously described (Miller et al.,
2013). Cells were plated on collagen-treated plates in DMEM supplemented with
10% fetal bovine serum. After a 2-3 hr attachment period, cells were washed
twice with PBS and incubated in serum-free Krebs-Ringer Bicarbonate Buffer
(Sigma-Aldrich, Cat. K4002) supplemented with 20mM HEPES, pH 7.4 and 0.5%
BSA for 2 hours. Media was collected and hemoglobin (Sigma Aldrich, Cat.
H2625) was added as a carrier protein (final concentration of 0.1%, w/v). For
trichloroacetic acid (TCA) precipitation, 1 volume of 100% TCA (w/v) was added
to 4 volume of sample to precipitate total protein. The protein pellet was washed
twice in ice-cold acetone, dried, and re-suspended in Laemmli sample buffer
(volume adjusted based on cellular protein content). Albumin in the samples was
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then measured by Western blotting (Anti-Alb, Nordic Immunology, Cat.
RAM/Alb/7s).

mRNA isolation and real-time PCR
Total RNA was isolated from frozen livers or primary hepatocytes using
the Nucleospin RNA Mini Kit (Clontech Labs, Cat. 740955.250). cDNA was
synthesized using M-MLV reverse transcriptase (New England Biolabs, Cat.
M0253S). Liver cDNA from transgenic mice expressing a constitutively active
Foxo1 was a generous gift from Dr. Terry G. Unterman (University of Illinois at
Chicago College of Medicine) (Deng et al., 2012). The relative expression of
genes of interest was quantified by real-time PCR using the SYBR Green Dyebased assay.

Serum albumin measurement
Blood samples were collected post sacrifice by cardiac puncture. After
allowing the blood to clot, the samples were centrifuged to separate the sera.
Albumin levels were measured using the BCG Albumin Assay Kit (Sigma Aldrich,
Cat. MAK124).

Streptozotocin-induced Type 1 diabetes
At 8 to 10 weeks of age, Foxo1loxP/loxP mice received a retro-orbital
injection of adeno-associated virus encoding either GFP or Cre recombinase at 1
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x 1011 genomic copies per mouse. 5 days after virus injection, mice received an
intra-peritoneal injection of either control buffer (0.1 M citrate, pH 4.5) or
streptozotocin (EMD Chemicals, Cat. 572201) at 200 mg per kg body weight.
Mice were sacrificed 2 weeks after virus injection (9 days after STZ injection).

Chromatin immunoprecipitation (ChIP) assay
Liver chromatin was prepared as previously described (Tuteja et al.,
2008). Immunoprecipitations were performed using anti-C/EBPα (Santa Cruz,
Cat. sc-61, 10µg per IP). Real-time PCR oligos used to measure occupancy are
listed below.

Statistical analysis
All values are expressed as mean ± SEM. Two-way ANOVA with
Bonferroni posttest was used if multiple conditions were involved when
comparing different genotypes. Two-tailed, unpaired Student’s t-test was used
when only two groups of data were concerned.
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Real-time PCR oligos used to measure C/EBPα occupancy
Alb-1f

CGCAAGGGATTTAGTCAAACAAC

Alb-1r

AACCATACTTACCTCGCATTTCA

Alb-2f

TCCCAGACCCATCAATTGTG

Alb-2r

TCCTGGCTCTTAGATTGCTCA

Alb-3f

AGCTAACCTTCTGTCCTAGTGG

Alb-3r

TGAACTCTGACTCACGATGGA

Alb-4f

ACAGAGGGTTGGATGGACAC

Alb-4r

CCTCATTACCTTTGTGCACCA

Cebpa-1f

AGGAGTCAGTGGGCGTTG

Cebpa-1r

GTCTTAGAGCCCGCCTTCTC

Cebpa-2f

TCCGTCTTCCTATACCAGTCTG

Cebpa-2r

CACCCAGTCCCAGTGATAGT

Cebpa-3f

CTTCAAGCAGATCCCAGGAAC

Cebpa-3r

CTAGTTCCGACCCTTCCTCC

Hsd11b1-1f

ATGGGCATCCTACAATTTCCT

Hsd11b1-1r

GGTCAGAGAACATTGGGGAAC

Hsd11b1-2f

CCAACTGGCCAGAAAATTGC

Hsd11b1-2r

ATTGGCACCCTTTCCCCTAA

Hsd11b1-3f

GGCTCGTCCTTGGCTTAGA

Hsd11b1-3r

GCTGGTGGTGGAAGTGAAAG
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